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1.	Supplemental	Tables	and	Figures	
Table	S1.	Preliminary	screen	for	functional	effects	of	five	pyrroloindoline	compounds	on	Cys	
loop	 receptors.	 In	 this	 screen	 five	 pyrroloindoline	 compounds	 (Figure	 S1),	 were	 tested	 for	
modulation	of	seven	pLGICs:	muscle	type	nAChR,	α4β2	nAChR,	α7	nAChR,	5‐HT3A	receptor,	α1β2γ2	
GABAA	receptor,	α1β2	GABAA	receptor,	GluR2,	and	the	glycine	receptor.	Relative	modulation	of	the	
current	 response	as	a	 result	of	co‐application	of	endogenous	agonist	EC50	dose	and	20‐40	 μM	of	
compound.	 Table	 adapted	 from	 Daeffler,	 K.N.‐M.	 2014	 and	 Marotta,	 C.B.	 2015.1,2	 Values	 are	
expressed	as	mean	±	SEM.	
Receptor	
AMAO‐1	
(%)	
AMAO‐1‐71	
(%)	
(±)‐2	(%)	
AMAO‐1‐98	
(%)	
AMAO‐1‐100	(%)	
Muscle	(9’)	 ‐21	±	1	 ‐29	±	3	 ‐53	±	3	 ‐7	±	3	 ‐81	±	6	
A3B2	
α4(L9’A)β2	
‐28	±	2	 ‐47	±	4	 ‐29	±	6	 ‐11	±	2	 ‐44	±	2	
Α7	(T6’S)	 ‐62	±	4	 ‐68	±	7	 ‐92	±	4	 ‐57	±	10	 ‐96	±	3	
5‐HT3A	 ‐3	±	2	 ‐23	±	4	 ‐3	±	5	 3	±	12	 ‐11	±	8	
α1β2γ2	GABAA	 ‐27	±	4	 ‐27	±	11	 52	±	10	 ‐27	±	21	 10	±	5	
α1β2	GABAA	 	 	 16	±	2	 	 	
GluR2	 ‐6	±	1	 0	±	2	 ‐9	±	6	 ‐11	±	5	 ‐12	±	5	
Glycine	 ‐6	 ‐9	±	9	 3	±	7	 18	±	10	 ‐16	±	6	
	
Table	 S2.	Relative	modulation	of	GABA	EC50	 responses	 in	WT	GABAA	 receptors.	Values	 are	
expressed	as	mean	±	SEM.	
Subtype	 Ligand	 Relative	modulation	of	GABA	EC50	(%)	 N	 |	Imax	|	(μA)	
α1β2γ2	 GABA	only	 ‐0.3	 ±	 1.6	 20	 0.49	–	7.7	
α1β2γ2	 0.08%	DMSO	 ‐5.5	 ±	 2.2	 8	 1.3	‐	33	
α1β2γ2	 (±)‐2	 17	 ±	 4.0	 14	 0.11	–	9.9	
α1β2γ2	 (‐)‐2	 ‐3.7	 ±	 3.7	 19	 0.31	–	10	
α1β2γ2	 (+)‐2	 16	 ±	 4.1	 14	 3.7	–	14	
α1β2	 (±)‐2	 28	 ±	 5.2	 10	 0.80	–	9.3	
α1β2	 (‐)‐2	 9.2	 ±	 1.1	 11	 0.30	–	2.3	
α1β2	 (+)‐2	 17	 ±	 2.6	 13	 0.44	–	3.3	
	
Table	 S3.	 EC50	 values	 of	 (+)‐2,	 GABA,	 and	 GABA	 co‐application	with	 (±)‐2,	 (–)‐11	 or	 (+)‐13.	
Values	are	expressed	as	mean	±	SEM.	
Subtype	 Compound	 EC50	(μM)	 ΔEC50	(μM)	 nH		 N	 |	Imax	|	(μA)	
α1β2γ2	 (+)‐2	 110	 ±	 4.9	 NA	 2.6	 ±	 0.3	 16	 0.91	‐	20	
α1β2γ2	 GABA	 23	 ±	 0.45	 0	 1.3	 ±	 0.03	 40	 1.7	‐	9.8	
α1β2γ2	 GABA	+	(±)‐2	 9.9	 ±	 0.48	 13	 1.7	 ±	 0.1	 22	 6.1	–	16	
α1β2γ2	 GABA	+	(‐)‐11	 14	 ±	 1.1	 9	 0.98	 ±	 0.08	 15	 1.0	–	30	
α1β2γ2	 GABA	+	(+)‐13	 6.9	 ±	 0.44	 16	 1.4	 ±	 0.1	 16	 6.1	–	26	
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Table	S4.	Relative	modulation	of	GABA	EC10	responses	by	(±)‐2	in	α1β2γ2	mutant	receptors.	
Values	are	expressed	as	mean	±	SEM.	
Mutant	 Relative	modulation	of	GABA	EC10	(%)	 N	 |	Imax	|	(μA)	
α1β2γ2	WT	 62	 ±	 6.1	 18	 0.77	–	4.4	
α1(H129R)β2γ2	 88	 ±	 8.1	 11	 0.026	–	0.77	
α1(Y209Q)β2γ2	 86	 ±	 8.9	 8	 0.18	‐2.3	
α1β2(Q88C)γ2	 69	 ±	 5.8	 10	 0.11	–	3.7	
α1(S297I)β2(N289I)γ2(S319I)	 1.1	 ±	 3.0	 12	 0.12	–	1.7	
α1(S297I)β2γ2	 41	 ±	 3.7	 12	 0.086	–	2.4	
α1β2(N289I)γ2	 9.7	 ±	 2.1	 12	 1.2	–	5.3	
α1β2γ2(S319I)	 66	 ±	 4.7	 10	 0.10	–	0.99	
α1(S297I)β2(N289I)γ2	 9.2	 ±	 2.0	 12	 0.36	–	2.5	
α1β2	WT		 38	 ±	 4.7	 9	 0.12	–	1.9	
α1(S297I)β2(N289I)	 ‐3.3	 ±	 13	 11	 0.032	–	0.84	
α1(S297I)β2	 16	 ±	 5.1	 9	 0.092	–	4.5	
α1β2(N289I)	 24	 ±	 16	 8	 0.046	–	1.2	
	
Table	S5.	GABA	EC50	values	of	GABAA	WT	and	mutant	receptors.	Values	are	expressed	as	mean	
±	SEM.	
Mutant	 EC50	(μΜ)	 nH	 N	 |Imax|(μA)	
α1β2γ2	WT	 23	 ±	 0.45	 1.3	 ±	 0.03	 40	 1.7	‐	9.8		
α1β2	WT	 3.0	 ±	 0.072	 1.5	 ±	 0.05	 7	 5.8	‐	25	
α1(H129R)β2γ2	 16	 ±	 0.47	 1.7	 ±	 0.06	 17	 0.37	–	4.0	
α1(Y209Q)β2γ2	 22	 ±	 0.81	 1.6	 ±	 0.08	 6	 4.2	‐	8.6	
α1β2(Q88C)γ2	 27	 ±	 1.8	 1.4	 ±	 0.1	 6	 0.93	–	8.0	
α1(S297I)β2(N289I)γ2(S319I)	 0.53	 ±	 0.010	 1.8	 ±	 0.05	 13	 3.5	–	6.4	
α1(S297I)β2γ2	 0.74	 ±	 0.021	 1.8	 ±	 0.08	 19	 1.1	‐	25	
α1β2(N289I)	γ2	 27	 ±	 0.59	 1.8	 ±	 0.06	 11	 0.04	‐	17	
α1β2γ2(S319I)	 20	 ±	 0.65	 1.7	 ±	 0.08	 6	 0.051	–	4.3	
α1(S297I)β2(N289I)γ2	 1.0	 ±	 0.028	 2.0	 ±	 0.09	 11	 2.9	‐	19	
α1(S297I)β2	 0.078	 ±	 0.0018	 2.1	 ±	 0.09	 20	 0.071	–	4.3	
α1β2(N289I)	 2.8	 ±	 0.075	 1.4	 ±	 0.05	 10	 1.0	–	3.7	
α1(S297I)β2(N289I)	 0.057	 ±	 0.0022	 2.2	 ±	 0.2	 7	 0.59	–	4.8	
	
Table	 S6.	 Relative	 modulation	 of	 GABA	 EC10	 responses	 of	 the	 α1β2γ2	 subtype	 by	
pyrroloindoline	derivatives.	Values	are	expressed	as	mean	±	SEM.	
Ligand	 RC3	 RN1	 RC5	 RC2	
Relative	
modulation	of	
GABA	EC10	(%)	
N	 |Imax|	(μA)	
(±)‐2	 OH	 Me	 H	 Ph	 62	 ±	 6.1	 18	 0.77	–	4.8	
(‐)‐2	 OH	 Me	 H	 Ph	 11	 ±	 2.2	 8	 2.1	–	3.6	
(+)‐2	 OH	 Me	 H	 Ph	 130	 ±	 15	 12	 0.47	–	6.0	
(‐)‐7	 OH	 NH	 H	 Ph	 1.8	 ±	 1.7	 14	 0.76	–	5.2	
(+)‐7	 OH	 NH	 H	 Ph	 41	 ±	 3.0	 15	 0.38	–	11	
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(‐)‐6	 OH	 Cbz	 H	 Ph	 25	 ±	 4.1	 14	 0.84	–	7.8	
(+)‐6	 OH	 Cbz	 H	 Ph	 9.6	 ±	 5.2	 14	 0.36	–	9.7	
(‐)‐10	 OMe	 Me	 H	 Ph	 24	 ±	 2.2	 6	 0.43‐1.2	
(+)‐10	 OMe	 Me	 H	 Ph	 21	 ±	 3.0	 5	 0.54‐0.84	
(‐)‐9	 F	 Me	 H	 Ph	 27	 ±	 3.0	 11	 0.73	–	8.3	
(+)‐9	 F	 Me	 H	 Ph	 100	 ±	 11	 16	 0.89	–	11	
(‐)‐14	 OH	 Me	 OMe	 Ph	 15	 ±	 4.6	 13	 0.48	–	3.7	
(+)‐14	 OH	 Me	 OMe	 Ph	 17	 ±	 3.2	 13	 0.73	–	13	
(‐)‐15	 OH	 Me	 Morpholine	 Ph	 21	 ±	 2.9	 11	 1.2	–	4.9	
(+)‐15	 OH	 Me	 Morpholine	 Ph	 ‐4.8	 ±	 1.8	 12	 0.89	–	8.7	
(‐)‐12	 OH	 Me	 CF3	 Ph	 1.3	 ±	 1.2	 16	 0.58	–	6.6	
(+)‐12	 OH	 Me	 CF3	 Ph	 110	 ±	 9.5	 16	 0.87	–	12	
(‐)‐13	 OH	 Me	 Br	 Ph	 31	 ±	 3.0	 10	 0.32	–	3.4	
(+)‐13	 OH	 Me	 Br	 Ph	 210	 ±	 21	 12	 2.3	–	19	
(‐)‐11	 OH	 Me	 I	 Ph	 230	 ±	 24	 16	 2.2	–	6.2	
(+)‐11	 OH	 Me	 I	 Ph	 35	 ±	 5.6	 15	 0.45	–	3.9	
(±)‐SI‐5	 OH	 Me	 H	 4‐OMe‐Ph	
‐
2.9*	
±	 1.6	 20	 0.082	–	11	
(‐)‐16	 OH	 Me	 H	 4‐Br‐Ph	 160	 ±	 11	 13	 0.63	–	6.8	
(+)‐16	 OH	 Me	 H	 4‐Br‐Ph	 98	 ±	 8.3	 15	 1.1	–	5.6	
*	relative	modulation	of	GABA	EC50.	
	
	
Figure	S1.	Pyrroloindoline	compounds	used	in	preliminary	screen.		
	
Figure	S2.	PAM	EC50	of	pyrroloindolines	(‐)‐11	and	(+)‐13	at	the	α1β2γ2	GABAA	receptor.	All	
PAM	doses	are	co‐applied	with	GABA	EC5	doses.	
	 	
 
 S5 
2.	Biological	Evaluation	Experimental	Procedures	
Molecular	biology	
Circular	DNA	of	human	GABAA	receptor	α1,	β2s	and	γ2s	subunits	were	in	a	pGEMhe	
plasmid.	For	both	β2s	and	γ2s	only	the	short	isoforms	were	used,	however	for	convenience	
we	refer	to	the	subunits	as	β2	and	γ2.	Site‐directed	mutagenesis	was	performed	using	the	
QuickChange	 protocol	 (Agilent	 Stratagene).	 cDNA	 in	 pGEMhe	 was	 linearized	 with	
restriction	 enzyme	NheI	 (for	 α1	 and	 γ2	 subunits),	 and	 Sph1	 (for	 the	 β2	 subunit)	 (New	
England	 Biolabs).	 Purified	 linear	DNA	 (Qiaquick	 PCR	 Purification	 kit,	 Qiagen)	was	 then	
transcribed	in	vitro	using	the	T7	mMessage	Machine	kit	(Ambion).	The	resulting	mRNA	was	
isolated	 using	 the	 RNeasy	 RNA	 purification	 kit	 (Qiagen)	 and	 quantified	 by	 UV‐vis	
spectroscopy	(NanoDrop	2000,	ThermoFisher	Scientific).	cDNA	and	mRNA	were	stored	at	‐
20˚C	and	‐80˚C	respectively.	
Oocyte	preparation	and	mRNA	injection	
Xenopus	 laevis	 oocytes	 (stage	 V‐VI)	 were	 harvested	 and	 injected	 with	 mRNA	
according	to	previously	described	protocols.3	Oocytes	were	injected	with	50‐75	nl	mRNA	in	
nuclease‐free	water.	Post	 injection,	oocytes	were	 incubated	at	18˚C	 in	ND96	solution	 (96	
mM	NaCl,	2mM	KCl,	1mM	MgCl2,	1.8	mM	CaCl2,	5	mM	HEPES,	pH	7.5)	supplemented	with	
0.05	mg/ml	gentamycin	(Sigma),	2.5	mM	sodium	pyruvate	(Acros	Organics),	and	0.67	mM	
theophylline	(Sigma).	
	 For	expression	of	wild‐type	α1β2γ2	receptors,	α1,	β2,	and	γ2	mRNA	were	mixed	in	
2:2:1	 ratio	by	mass.	For	expression	of	wild‐type	 α1β2	 receptors,	 α1	and	 β2	mRNA	were	
mixed	 in	1:1	 ratio	by	mass.	Each	 cell	was	 injected	with	5	ng	or	15	ng	mRNA	 in	a	 single	
injection	 for	 the	 α1β2γ2	 and	 α1β2,	 respectively.	Oocytes	were	 then	 incubated	 for	 24	 h	
before	 recording.	 Proper	 injection	 ratios	 for	 mutant	 receptors	 were	 determined	 after	
analysis	 of	 the	 dose‐response	 curve	 and	 optimized	 when	 necessary.	 All	 ECD	 mutant	
receptors	and	the	triple	TMD	mutant	were	 injected	with	a	2:2:1	ratio.	Injection	ratios	 for	
the	TMD	mutants	were	as	 follows:	 αMβγ	and	 αMβMγ:	2:2:1;	 αβMγ:	2:10:1;	 αβγM:	1:1:8;	
αMβ,	αβM	and	αMβM:	1:1.	
Electrophysiology	
All	 electrophysiological	 recordings	were	 performed	 using	 the	OpusXpress	 6000A	
(Axon	 Instruments)	 in	 two‐electrode	 voltage	 clamp	mode	 at	 ambient	 temperature	 (20‐
25˚C).	Oocytes	were	impaled	with	borosilicate	glass	pipettes	filled	with	3	M	KCl	(R	=	0.3‐3.0	
MΩ)	and	clamped	at	a	holding	potential	of	 ‐60	mV.	ND96	solution	with	Ca2+	was	used	as	
running	buffer.	GABA	and	test‐ligand	solutions	were	prepared	in	ND96	with	Ca2+	and	1	mL	
was	applied	over	15	 s	 followed	by	a	5	min	washout	with	buffer	at	a	 rate	of	3	mL	min‐1	
(chamber	 volume,	 500	 μL).	 Data	 for	 each	 condition	 were	 obtained	 from	 at	 least	 two	
different	batches	of	oocytes.	Data	were	sampled	at	50	Hz.	
For	potentiation	experiments	an	adapted	protocol,	previously	described	by	Marotta	
2015,	 	was	 used.2	 The	 protocol	 is	 as	 follows:	 three	 identical	GABA	 doses	were	 applied,	
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followed	by	a	dose	of	the	test‐ligand	at	40	μM.	After	a	30	s	 incubation	period,	a	test	dose	
was	applied	 containing	both	GABA	and	 the	 test‐ligand.	Finally,	 two	doses	of	GABA	were	
applied.	 The	 first	 test	 dose	 evaluates	 agonism	 properties,	 the	 second	 dose	 tests	 for	
modulation	of	the	GABA	response,	which	can	be	potentiating	or	inhibiting.	The	first	three	
GABA	doses	aim	to	establish	a	baseline	of	the	GABA	response	at	that	concentration,	and	the	
purpose	of	 the	 last	 two	GABA	doses	 is	 to	verify	proper	 functioning	of	 the	 receptor	post	
modulation	 and	 control	 for	 independent	 rise	 in	 current	 amplitude.	 Dose‐response	
measurements	were	 performed	 using	 a	 series	 of	~2‐fold	 concentration	 steps,	 spanning	
multiple	orders	of	magnitude,	for	a	total	of	8‐24	doses.		
Two‐electrode	 voltage‐clamp	 traces	 were	 processed	 in	 Clampfit	 10.3	 (Axon	
Instruments).	Raw	traces	were	filtered	using	a	low	pass	Gaussian	filter	at	5	Hz,	followed	by	
a	subtraction	of	the	average	baseline	current	preceding	ligand	application.	For	potentiation	
experiments	the	current	responses	from	the	five	GABA	doses	were	averaged	(GABA	only)	
and	subtracting	this	from	the	response	of	the	co‐application	dose	(GABA	+	test‐ligand)	gave	
the	 calculated	 change	 in	 response.	Multiplying	 this	value	by	100%	 rendered	 the	 relative	
modulation	 (inhibition/potentiation)	 of	 the	 GABA	 response	 by	 the	 test‐ligand.	 Relative	
modulation	 is	 reported	as	 the	mean	±	 standard	error	of	 the	mean	 (SEM).	For	 the	GABA	
concentration	either	the	EC50	or	EC10	was	used	as	specified	in	the	results	section.	For	dose‐
response	experiments,	normalized	peak	currents	were	averaged	and	fit	to	the	Hill	equation,	
Inorm	=	1/(1	+	 (EC50/[agonist]nH)	 in	Prism	8	 (GraphPad	Software,	 Inc.),	where	 Inorm	 is	 the	
normalized	peak	current	at	a	given	agonist	concentration,	EC50	is	the	agonist	concentration	
that	 elicits	 a	 half‐maximum	 response,	 and	 nH	 is	 the	Hill	 coefficient.	 Peak	 currents	were	
normalized	 to	 the	maximum	current	observed	 for	 that	cell.	Unless	otherwise	stated,	EC50	
and	nH	data	are	shown	as	mean	±	standard	error	of	the	mean	(SEM).	Geometry	calculations	
were	performed	in	Spartan	14	v1.1.9.		
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3.	Materials	and	Methods	Synthetic	Chemistry	
	 Unless	 otherwise	 stated,	 reactions	were	 performed	 under	 a	nitrogen	 atmosphere	
using	 freshly	 dried	 solvents.	Methylene	 chloride	 (CH2Cl2),	 diethyl	 ether	 (Et2O),	 toluene	
(PhMe),	tetrahydrofuran	(THF),	and	1,4‐dioxane	were	dried	by	passing	through	activated	
alumina	 columns.	 Triethylamine	 (Et3N)	 and	 N,N‐diisopropylethylamine	 (i‐Pr2NEt)	 were	
distilled	 over	 calcium	hydride	prior	 to	use.	3Å	molecular	 sieve	pellets	were	 flame‐dried	
under	 high	 vacuum	 prior	 to	 use.	 N‐chlorosuccinimide	was	 purified	 by	 recrystallization	
from	AcOH	and	N‐bromosuccinimide	was	purified	by	recrystallization	from	water	prior	to	
use.	All	 other	 commercially	 obtained	 reagents	were	 used	 as	 received	 unless	 specifically	
indicated.	All	reactions	were	monitored	by	 thin‐layer	chromatography	using	EMD/Merck	
silica	gel	60	F254	pre‐coated	plates	(0.25	mm)	and	were	visualized	by	UV	and/or	KMnO4	
staining.	Silica	gel	column	chromatography	was	performed	as	described	by	Still	et	al.	using	
silica	 gel	 (230–400	 mesh)	 purchased	 from	 Silicycle.4	 1H	 and	 13C	 NMR	 spectra	 were	
recorded	 on	 a	 Varian	 Inova	 500	 (at	 500	MHz	 and	 125	MHz	 respectively)	 or	 a	 Bruker	
Avance	III	HD	with	Prodigy	cyroprobe	(at	400	MHz	and	101	MHz	respectively).	NMR	data	is	
reported	relative	to	internal	chloroform	or	acetonitrile	solvent	peaks	(with	respect	to	TMS	
(tetramethylsilane)):	CDCl3,	1H,	δ	=	7.26,	13C,	δ	=	77.16;	CD3CN,	1H,	δ	=	1.94,	13C,	δ	=	118.26).	
19F	spectra	were	recorded	on	a	Varian	300	MHz	spectrometer.	NMR	data	are	reported	as	
follows:	 chemical	 shift	 (δ	 ppm)	 (multiplicity,	 coupling	 constant	 (Hz),	 integration).	
Multiplicity	and	qualifier	abbreviations	are	as	follows:	s	=	singlet,	d	=	doublet,	t	=	triplet,	q	=	
quartet,	m	=	multiplet,	br	=	broad.	 IR	spectra	were	 recorded	on	a	Perkin	Elmer	Paragon	
1000	spectrometer	and	are	reported	 in	 frequency	of	absorption	 (cm–1).	Optical	rotations	
were	measured	on	a	Jasco	P‐2000	polarimeter	using	a	100	mm	path‐length	cell	at	589	nm.	
HRMS,	analytical	SFC,	and	preparative	chiral	resolution	experiments	were	performed	at	the	
Caltech	Center	 for	Catalysis	and	Chemical	Synthesis.	HRMS	data	were	acquired	using	an	
Agilent	 6200	 Series	 TOF	with	 an	 Agilent	 G1978A	Multimode	 source	 using	 electrospray	
ionization	(ESI).	Analytical	chiral	SFC	was	performed	with	a	Mettler	SFC	supercritical	CO2	
analytical	chromatography	system	 (CO2	=	1450	psi,	column	 temperature	=	40	 °C)	with	a	
Chiralpak	AD‐H	column	(4.6	mm	x	25	cm).	Preparative	chiral	resolution	of	pyrroloindoline	
(±)‐2	was	achieved	using	an	Agilent	1200	series	HPLC	with	a	20	x	250	mm	5	µm	Daicel	IC	
chiral	 preparative	 HPLC	 column.	 Preparative	 chiral	 resolution	 of	 carbamate	 (±)‐6	 and	
bromocarbamate	(±)‐SI‐3	were	achieved	using	a	Jasco	2000	series	preparative	SFC	system	
with	a	21.2	x	250	mm	5	µm	AD‐H	column.	
Abbreviations	used:	Et2O	–	diethyl	ether;	PhMe	–	 toluene;	EtOAc	–	ethyl	acetate;	THF	–	
tetrahydrofuran;	Et3N	–	triethylamine;	i‐Pr2NEt	–	N,N‐diisopropylethylamine. 
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4.	Experimental	Procedures	for	Preparation	of	Pyrroloindolines	
	
Synthesis	of	the	Pyrroloindoline	Core		
	
	
A	 flame‐dried	 100	mL	 round‐bottom	 flask	 was	 charged	 with	 tryptamine	 (2.0	 g,	 12.48	
mmol)	and	chloroform	(20	mL).	Then	i‐Pr2NEt	(4.4	mL,	25.34	mmol,	2.03	equiv)	and	benzyl	
chloroformate	 (2.0	 mL,	 14.11	 mmol,	 1.13	 equiv)	 were	 added	 dropwise	 via	 syringe	
successively.	After	stirring	at	ambient	temperature	for	1	h,	water	was	added	(10	mL)	and	
the	 layers	were	separated.	The	aqueous	 layer	was	extracted	with	CH2Cl2	(10	mL	x	2)	and	
the	combined	organic	layers	were	dried	(MgSO4),	filtered,	and	concentrated	under	reduced	
pressure.	 The	 crude	 residue	 was	 dry‐loaded	 with	 Celite	 and	 purified	 by	 silica	 gel	
chromatography	 (10–66%	EtOAc/hexanes)	 to	afford	SI‐1	 (3.3	g,	90%	yield)	as	a	 slightly	
pink	 off‐white	 solid.	 The	 spectral	 data	 were	 in	 agreement	 with	 those	 reported	 in	 the	
literature.5	
	
	
A	 flame‐dried	100	mL	round‐bottom	 flask	was	charged	with	SI‐1	 (1.5	g,	5.10	mmol)	and	
acetone	(21	mL).	Potassium	hydroxide	(1.43	g,	25.48	mmol,	5.0	equiv)	was	ground	with	a	
mortar	 and	 pestle	 to	 a	 fine	 powder	 and	 added	 to	 the	 reaction,	which	was	 then	 stirred	
vigorously	for	10	min.	To	the	yellow‐orange	suspension	was	added	methyl	iodide	(0.35	mL,	
5.61	mmol,	 1.1	 equiv)	 dropwise	 via	 syringe.	 After	 stirring	 for	 1	 h,	 a	 second	 portion	 of	
potassium	hydroxide	(1.43	g,	25.48	mmol,	5.0	equiv)	ground	with	a	mortar	and	pestle	to	a	
fine	powder	was	added	to	the	reaction,	followed	by	a	second	charge	of	methyl	iodide	(0.35	
mL,	5.61	mmol,	1.1	equiv)	dropwise	via	syringe.	The	suspension	was	stirred	for	1	h.	Water	
(12	mL)	was	added	and	the	reaction	was	stirred	for	an	additional	15	min.	The	acetone	was	
removed	 by	 rotary	 evaporation.	 Saturated	 aqueous	 NaCl	 (3	 mL)	 was	 added	 and	 the	
solution	was	extracted	with	CH2Cl2	(20	mL	x	4).	The	combined	organic	extracts	were	dried	
(MgSO4),	 filtered,	 and	 concentrated	 under	 reduced	 pressure.	 The	 crude	 residue	 was	
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purified	by	silica	gel	chromatography	(10–33%	EtOAc/hexanes)	 to	afford	4	(1.60	g,	95%	
yield)	as	a	viscous	yellow	oil.	The	spectral	data	were	in	agreement	with	those	reported	in	
the	literature.6	
	
	
On	a	benchtop,	 two	10–20	mL	microwave	vials	were	each	charged	with	4	 (650	mg,	2.11	
mmol),	DMF	 (8.5	mL),	2‐nitrobenzoic	acid	 (528	mg,	3.16	mmol,	1.5	equiv),	 iodobenzene	
(0.95	mL,	8.43	mmol,	4.0	equiv),	Pd(OAc)2	(24	mg,	0.11	mmol,	0.05	equiv),	and	then	AgBF4	
(615	mg,	3.16	mmol,	1.5	equiv).	A	magnetic	vane	stirbar	was	added	and	the	reactions	were	
flushed	with	argon	and	capped	using	a	microwave	vial	crimper.	The	mixtures	were	 then	
stirred	vigorously	 (660	 rpm)	 in	 the	dark	 for	40	min	at	ambient	 temperature.	The	black‐
brown	 opaque	 solutions	were	 then	 subjected	 to	microwave	 irradiation	 using	 a	 Biotage	
microwave	 reactor	 at	 150	 °C	 for	 4	min	 (stirring	 at	 660	 rpm).	 The	 reactions	were	 each	
filtered	 through	 a	 small	 plug	 of	 Celite,	 eluting	with	 EtOAc	 (30	mL).	 The	 filtrates	were	
combined	 and	 washed	 with	 saturated	 aqueous	 NH4Cl	 (25	mL	 x	 2),	 saturated	 aqueous	
NaHCO3	(25	mL	x	2),	and	brine	(25	mL	x	2).	The	organic	layer	was	dried	(MgSO4),	filtered,	
and	 concentrated	 under	 reduced	 pressure.	 The	 crude	 residue	was	 purified	 by	 silica	 gel	
chromatography	 (5–25%	 EtOAc/hexanes)	 to	 afford	 5	 (1.251	 g,	 77%	 yield)	 as	 a	 viscous	
reddish	yellow	oil.		
TLC	Rf	=	0.47	in	25%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CDCl3,	compound	exists	as	a	6:1	mixture	of	rotamers,	the	major	rotamer	
is	designated	by	*,	minor	rotamer	designated	by	§)	δ	7.68	(d,	 J	=	7.9	Hz,	1H*),	7.54	(br	s,	
1H§),	7.50	–	7.41	(m,	3H*,	3H§),	7.40	–	7.26	(m,	9H*,	9H§),	7.17	(t,	J	=	7.4	Hz,	1H*),	7.12	(br	
s,	1H§),	5.04	(s,	2H*,	2H§),	4.74	(t,	J	=	6.8	Hz,	1H*),	4.53	(br	s,	1H§),	3.59	(s,	3H*,	3H§),	3.44	
(td,	J	=	6.7,	6.7	Hz,	2H*),	3.38	(br	s,	2H§),	2.94	(t,	J	=	6.9	Hz,	2H*),	2.90	(br	s,	2H§)	ppm.	
13C	NMR	(101	MHz,	CDCl3;	compound	exists	as	a	6:1	mixture	of	rotamers,	only	the	major	
rotamer	is	reported)	δ	156.3,	139.0,	137.2,	131.8,	130.7,	128.7,	128.6,	128.4,	128.1,	122.0,	
119.6,	119.0,	109.6,	66.5,	41.8,	30.9,	25.2	ppm.	
FTIR	(NaCl/thin	film):	3413,	3339,	3055,	3030,	2940,	1718,	1701,	1511,	1368,	1361,	1334,	
1233,	1132	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C25H25N2O2	[M+H]+:	385.1911,	found:	385.1924.	
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A	flame‐dried	100	mL	round‐bottom	flask	was	charged	with	5	(900	mg,	2.34	mmol),	MeCN	
(23	 mL),	 and	 3Å	 molecular	 sieve	 pellets	 (1.2	 g,	 1.3	 x	 mass	 of	 5).	 A	 solution	 of	 N‐
chlorosuccinimide	(319	mg,	2.39	mmol,	1.02	equiv)	in	MeCN	(47	mL)	was	added	dropwise	
over	10	min.	The	flask	was	wrapped	in	aluminum	foil	and	stirred	in	the	dark	for	3.5	h.	TLC	
analysis	 indicated	 consumption	 of	 starting	 material	 (Rf	 of	 the	 putative	 chloride	
intermediate	 =	 0.56;	 25%	 EtOAc/hexanes,	UV,	KMnO4).	Water	 (47	mL)	was	 then	 added	
dropwise	and	the	reaction	was	stirred	for	1	h.	The	reaction	mixture	was	filtered	through	a	
Celite	 pad	 and	 rinsed	 copiously	 with	 EtOAc.	 A	 2:1	 mixture	 of	 saturated	 aqueous	
NaHCO3/brine	(20	mL)	was	added	and	 the	 layers	were	separated	 in	a	separatory	 funnel.	
The	 aqueous	 layer	 was	 extracted	 with	 EtOAc	 (25	 mL	 x	 3)	 and	 the	 combined	 organic	
extracts	 were	 dried	 (Na2SO4),	 filtered,	 and	 concentrated	 under	 reduced	 pressure.	 The	
crude	 residue	 was	 purified	 by	 silica	 gel	 chromatography	 (10–30%	 EtOAc/hexanes)	 to	
afford	(±)‐6	(845	mg,	85%	yield)	as	a	yellow	orange	foam.		
TLC	Rf	=	0.32	in	25%	EtOAc/hexanes	(UV,	KMnO4).	
1H	 NMR	 (400	MHz,	 CDCl3,	 compound	 exists	 as	 a	 1.1:1	mixture	 of	 rotamers,	 the	major	
rotamer	is	designated	by	*,	minor	rotamer	designated	by	§)	δ	7.48	–	7.09	(m,	11H*,	11H§),	
6.78	(td,	J	=	7.4,	1.7	Hz,	2H*),	6.75	–	6.68	(m,	2H§),	6.58	(d,	J	=	7.8	Hz,	1H*),	6.50	(d,	J	=	7.9	
Hz,	1H§),	5.12	(d,	J	=	12.4	Hz,	1H*),	5.05	(s,	1H*),	5.02	(s,	1H§),	4.85	(d,	J	=	12.4	Hz,	1H§),	
4.05	(dd,	J	=	10.8,	8.5	Hz,	1H§),	3.98	(ddd,	J	=	10.5,	8.4,	1.8	Hz,	1H*),	3.30	(td,	J	=	11.1,	6.2	Hz,	
1H*),	3.21	(td,	J	=	11.4,	5.9	Hz,	1H§),	3.04	(s,	3H*),	2.76	(s,	3H§),	2.55	–	2.36	(m,	2H*),	2.33	–	
2.13	(m,	2H§),	1.44	(br	s,	1H*,	1H§)	ppm.	
13C	NMR	(101	MHz,	CDCl3;	compound	exists	as	a	1.1:1	mixture	of	rotamers)	δ	155.1,	154.6,	
151.3,	 151.1,	 136.8,	 135.7,	 130.9,	 128.8,	 128.6,	 128.4,	 128.3,	 128.1,	 128.0,	 127.9,	 127.7,	
127.52,	127.46,	123.79,	123.76,	118.3,	118.0,	106.7,	106.6,	94.4,	93.7,	89.8,	88.7,	67.1,	66.9,	
46.5,	46.3,	34.3,	33.8,	32.0,	31.4	ppm.		
FTIR	(NaCl/thin	film):	3049,	3056,	3032,	2945,	2891,	1695,	1684,	1675,	1609,	1491,	1401,	
1348,	1186,	1117,	1004	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C25H25N2O3	[M+H]+:	401.1860,	found:	401.1877.	
	
 
 S11 
	
Preparative	chiral	SFC	resolution:	Carbamate	 (±)‐6	 (219	mg)	was	dissolved	 in	a	minimal	
amount	 of	 i‐PrOH	 (~4	 mL).	 This	 solution	 of	 racemic	 compound	 was	 resolved	 by	
preparative	chiral	SFC,	serially	 injecting	200	µL	at	a	time	(isocratic:	40%	 i‐PrOH	/CO2)	to	
afford	(–)‐6	(92	mg)	and	(+)‐6	(85	mg)	as	yellow	foams.		
(+)‐6:	
[α]D25	=	+437.3°	(c	=0.975,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	30%	i‐PrOH/CO2;	retention	time	=	10.4	min).	
(–)‐6:	
[α]D25	=	–407.4°	(c	=	0.995,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	30%	i‐PrOH/CO2;	retention	time	=	6.6	min).	
	
Chiral	SFC	trace	of	(±)‐6	(30%	i‐PrOH/CO2): 	
	
	
	
	
	
	
	
	
	
	
	
(±)‐6 
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Chiral	SFC	trace	of	(+)‐6	(30%	i‐PrOH/CO2):	
	
	
	
Chiral	SFC	trace	of	(–)‐6	(30%	i‐PrOH/CO2): 	
	
	
	
	
A	flame‐dried	50	mL	round‐bottom	flask	was	charged	with	(±)‐6	(500	mg,	1.25	mmol)	and	
PhMe	 (25	mL).	 Red‐Al	 (60	 wt%	 in	 PhMe,	 3.25	mL,	 9.99	mmol,	 8.0	 equiv)	 was	 added	
dropwise.	Gas	evolution	was	observed	during	the	addition.	After	stirring	for	5	min,	the	flask	
was	flushed	with	argon,	sealed,	and	the	reaction	was	stirred	at	80	°C	for	2.5	h.	The	reaction	
was	cooled	to	room	temperature	and	then	slowly	quenched	with	a	1	M	aqueous	solution	of	
Rochelle’s	salt	(6.5	mL).	The	resulting	mixture	was	stirred	for	1	h	and	then	extracted	with	
Et2O	 (15	 mL	 x	 4).	 The	 combined	 organic	 extracts	 were	 dried	 (MgSO4),	 filtered,	 and	
(–)‐6 
(+)‐6 
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concentrated	 under	 reduced	 pressure.	 The	 crude	 residue	 was	 purified	 by	 silica	 gel	
chromatography	(10–20%	EtOAc/hexanes)	to	afford	(±)‐2	(340	mg,	97%	yield)	as	a	yellow	
solid.		
TLC	Rf	=	0.27	in	33%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(500	MHz,	CDCl3)	δ	7.45	–	7.35	(br	s,	2H),	7.32	(tt,	J	=	7.2,	1.4	Hz,	1H),	7.28	–	7.19	
(m,	2H),	6.71	(td,	J	=	7.3,	1.0	Hz,	1H),	6.43	(d,	J	=	7.8,	1H),	3.03	(ddd,	J	=	9.1,	5.0,	2.8	Hz,	1H),	
2.77	(s,	3H),	2.66	–	2.53	(m,	1H),	2.48	(s,	3H),	2.33	–	2.19	(m,	2H),	1.39	(br	s,	1H)	ppm.	Note:	
A	 total	 of	 7H	 aromatic	 protons	 observed	with	 relaxation	 delay	 =	 1	 sec;	 9H	 expected	 if	
relaxation	delay	is	>	5	sec.	
13C	NMR	(126	MHz,	CDCl3)	δ	152.7,	137.5,	130.9,	130.0,	128.9,	128.2,	124.1,	117.0,	110.1,	
104.1,	98.4,	90.8,	51.6,	40.7,	36.7,	34.5	ppm.	
FTIR	(NaCl/thin	film):	3540,	3435,	3051,	2931,	2791,	1608,	1492,	1473,	1445,	1370,	1308,	
1106,	1028	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C18H21N2O	[M+H]+:	281.1648,	found:	281.1655.	
	
	
Preparative	chiral	HPLC	resolution:	Pyrroloindoline	(±)‐2	(187	mg)	was	dissolved	in	15	mL	
of	 9:1	 hexanes/IPA.	This	 solution	 of	 racemic	 compound	was	 resolved	 using	preparative	
chiral	HPLC,	injecting	serially	260	µL	at	a	time	(isocratic:	4%	i‐PrOH/hexanes)	to	afford	(–)‐
2	(88	mg)	and	(+)‐2	(85	mg)	as	light	yellow	solids.		
(+)‐2:	
[α]D25	=	+26.4°	(c	=	1.00,	CHCl3).	
SFC:	98.4%	ee	(AD‐H	column:	12	min,	15%	i‐PrOH/CO2;	retention	time	=	6.9	min).	
(–)‐2:	
[α]D25	=	–26.6°	(c	=	1.00,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	15%	i‐PrOH/CO2;	retention	time	=	8.4	min).	
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Chiral	SFC	trace	for	(±)‐2	(15%	i‐PrOH/CO2):	
	
	
Chiral	SFC	trace	for	(+)‐2	(15%	i‐PrOH/CO2):	
	
	
Chiral	SFC	trace	for	(–)‐2	(15%	i‐PrOH/CO2):	
	
	
	
(+)‐2 
(±)‐2 
(–)‐2 
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Derivatization	of	the	Pyrroloindoline	Framework	
	
	
A	25	mL	round‐bottom	flask	containing	(+)‐6	(27	mg,	67	µmol)	was	charged	with	THF	(1.9	
mL),	 Et3SiH	 (430	 µL,	 2.7	 mmol,	 40	 equiv),	 Et3N	 (20	 µL,	 135	 µmol,	 2.0	 equiv),	 and	
Pd2(dba)3•CHCl3	(14	mg,	130	µmol,	0.2	equiv).	The	flask	was	sealed	under	argon,	wrapped	
in	aluminum	foil,	and	heated	to	50	°C.	After	stirring	for	18	h,	the	dark	purple	red	solution	
was	cooled	to	room	temperature.	Saturated	aqueous	NaHCO3	(2	mL)	was	then	added	and	
the	 solution	was	 stirred	at	23	 °C	 for	5	h.	The	white	 suspension	was	 then	extracted	with	
EtOAc	 (5	mL	 x	4)	 and	 the	 combined	 organic	 extracts	were	dried	 (Na2SO4),	 filtered,	 and	
concentrated	 under	 reduced	 pressure.	 The	 crude	 residue	 was	 purified	 by	 silica	 gel	
chromatography	(10–40%	EtOAc/hexanes)	to	afford	(+)‐7	(13.0	mg,	72%	yield)	as	a	white	
solid.		
	
	
The	same	procedure	was	performed	on	(–)‐6	(30	mg,	75	µmol)	to	afford	(–)‐7	(9.0	mg,	45%	
yield)	as	a	white	solid.		
(+)‐7:	
[α]D25	=	+54.6°	(c	=	0.65,	MeOH).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	30%	i‐PrOH/CO2;	retention	time	=	7.6	min).	
(–)‐7:	
[α]D25	=	–53.2°	(c	=	0.45,	MeOH).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	30%	i‐PrOH/CO2;	retention	time	=	6.8	min).	
	
TLC	Rf	=	0.19	in	33%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CD3CN)	δ	7.45	–	7.38	(m,	2H),	7.34	(ddd,	J	=	8.1,	6.9,	1.2	Hz,	2H),	7.30	–	
7.24	(m,	1H),	7.17	–	7.11	(m,	2H),	6.62	(td,	J	=	7.4,	1.0	Hz,	1H),	6.42	(dd,	J	=	8.2,	1.0	Hz,	1H),	
3.14	(ddd,	J	=	9.5,	5.1,	3.5	Hz,	1H),	2.68	(td,	J	=	9.4,	7.8	Hz,	1H),	2.64	(br	s,	1H),	2.57	(s,	3H),	
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2.23	–	2.10	(m,	2H)	ppm.	Note:	One	of	the	N–H/O–H	protons	was	not	observed	under	these	
conditions.	
13C	NMR	(101	MHz,	CD3CN)	δ	152.7,	140.9,	132.4,	130.5,	128.9,	128.8,	128.3,	124.7,	117.3,	
105.1,	95.2,	90.4,	43.8,	42.9,	28.6	ppm.	
FTIR	3307,	3053,	2930,	2857,	1608,	1494,	1371,	1306,	1206,	1121,	1058,	1016	(NaCl/thin	
film):	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C17H19N2O	[M+H]+:	267.1492,	found:	267.1495.	
	
	
	
A	 flame‐dried	25	mL	 round‐bottom	 flask	was	 charged	with	 (+)‐6	 (30	mg,	75	µmol)	 and	
CH2Cl2	(2.0	mL).	The	solution	was	cooled	to	–78	°C	and	a	solution	of	Et2N•SF3	(30	µL,	225	
µmol,	 3.0	 equiv)	 in	 CH2Cl2	 (0.5	mL)	was	 added	 dropwise	 and	 then	 stirred	 for	 1	 h.	 The	
reaction	was	allowed	to	warm	to	–40	°C	and	stirred	for	an	additional	1	h.	The	reaction	was	
then	 slowly	 quenched	 at	 this	 temperature	with	 saturated	 aqueous	NaHCO3	 (3	mL).	The	
resulting	mixture	was	extracted	with	CH2Cl2	(4	mL	x	3)	and	the	combined	organic	extracts	
were	dried	(Na2SO4),	filtered,	and	concentrated	under	reduced	pressure.	The	crude	residue	
was	purified	by	 silica	 gel	 chromatography	 (10–25%	EtOAc/hexanes)	 to	 afford	 (+)‐8	 (19	
mg,	64%	yield)	as	a	yellow	viscous	oil.		
	
	
The	same	procedure	was	performed	on	(–)‐6	(17	mg,	61	µmol)	to	afford	(–)‐8	(18	mg,	61%	
yield)	as	a	yellow	viscous	oil.		
(+)‐8:	
[α]D25	=	+416.1°	(c	=	0.63,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	20%	i‐PrOH/CO2;	retention	time	=	8.0	min).	
(–)‐8:	
[α]D25	=	–429.7°	(c	=	0.65,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	20%	i‐PrOH/CO2;	retention	time	=	11.1	min).	
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TLC	Rf	=	0.26	in	15%	EtOAc/hexanes	(UV,	KMnO4).	
1H	 NMR	 (400	MHz,	 CDCl3,	 compound	 exists	 as	 a	 1.1:1	mixture	 of	 rotamers,	 the	major	
rotamer	is	designated	by	*,	minor	rotamer	designated	by	§)	δ	7.51	–	7.28	(m,	10H*,	10H§),	
7.18	(dt,	J	=	14.7,	7.2	Hz,	1H*,	1H§),	6.86	–	6.73	(m,	2H*,	2H§),	6.61	(d,	J	=	8.0	Hz,	1H*),	6.53	
(d,	J	=	8.0	Hz,	1H§),	5.14	(d,	J	=	12.5	Hz,	1H*),	5.11	–	4.99	(m,	1H*,	1H§),	4.89	(d,	J	=	12.3	Hz,	
1H§),	4.22	–	4.07	(m,	1H§),	4.03	(t,	J	=	9.7	Hz,	1H*),	3.35	(dd,	J	=	11.5,	6.3	Hz,	1H*),	3.26	(td,	J	
=	11.9,	11.4,	6.4	Hz,	1H§),	3.04	(s,	3H*),	2.75	(s,	3H§),	2.67	–	2.37	(m,	2H*,	2H§)	ppm.	
13C	NMR	(101	MHz,	CDCl3;	compound	exists	as	a	1.1:1	mixture	of	rotamers)	δ	155.1,	154.4,	
152.4,	 152.2,	 136.7,	 135.6,	 135.4,	 134.4,	 132.2,	 132.2,	 128.6,	 128.5,	 128.4,	 128.2,	 128.1,	
128.0,	127.9,	127.8,	124.7,	124.6,	123.3,	123.1,	118.2,	117.9,	106.9,	92.9,	92.6,	77.5,	77.2,	
76.8,	67.3,	67.0,	46.3,	46.2,	32.0,	31.5,	31.2,	30.9	ppm.	
FTIR	 3034,	 2927,	 2894,	 1714,	 1613,	 1493,	 1448,	 1401,	 1340,	 1191,	 1104,	 1004,	 960	
(NaCl/thin	film):	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C25H24FN2O2	[M+H]+:	403.1816,	found:	403.1799.	
	
	
	
A	 flame‐dried	25	mL	round‐bottom	 flask	was	charged	with	(+)‐8	(12.5	mg,	31	µmol)	and	
PhMe	(620	µL).	Red‐Al	(60	wt%	in	PhMe,	80	µL,	248	µmol,	8.0	equiv)	was	added	dropwise.	
After	 stirring	 for	 5	min,	 the	 flask	was	 flushed	with	 argon,	 sealed,	 and	 the	 reaction	was	
stirred	at	80	 °C	 for	1.5	h.	The	solution	was	cooled	 to	room	 temperature	and	 then	slowly	
quenched	with	a	1	M	aqueous	solution	of	Rochelle’s	salt	(1	mL).	The	resulting	mixture	was	
stirred	vigorously	for	1	h	and	then	extracted	with	Et2O	(3	mL	x	4).	The	combined	organic	
extracts	were	dried	(MgSO4),	filtered,	and	concentrated	under	reduced	pressure.	The	crude	
residue	was	purified	by	silica	gel	chromatography	(2–7%	EtOAc/hexanes)	to	afford	(+)‐9	
(6.8	mg,	77%	yield)	as	a	white	crystalline	solid.		
	
	
The	same	procedure	was	performed	on	(–)‐8	(13	mg,	32	µmol)	to	afford	(–)‐9	(6.4	mg,	70%	
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yield)	as	a	white	crystalline	solid.		
(+)‐9:	
[α]D25	=	+62.0°	(c	=	0.34,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	5%	i‐PrOH/CO2;	retention	time	=	5.3	min).	
(–)‐9:	
[α]D25	=	–78.9°	(c	=	0.32,	CHCl3).	
SFC:	99%	ee	(AD‐H	column:	12	min,	5%	i‐PrOH/CO2;	retention	time	=	10.8	min).	
	
TLC	Rf	=	0.57	in	5%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CDCl3)	δ	7.42	–	7.29	(m,	5H),	7.28	(d,	J	=	1.7	Hz,	1H),	7.26	(d,	J	=	1.5	Hz,	
1H),	6.73	(tt,	J	=	7.4,	0.8	Hz,	1H),	6.47	(dq,	J	=	7.6,	1.1	Hz,	1H),	3.15	–	2.99	(m,	1H),	2.73	(d,	J	
=	0.9	Hz,	3H),	2.64	–	2.40	(m,	2H),	2.47	(s,	3H),	2.39	–	2.28	(m,	1H)	ppm.	
13C	NMR	(101	MHz,	CDCl3)	δ	153.5	(d,	J	=	5.2	Hz),	136.3	(d,	J	=	6.3	Hz),	131.1	(d,	J	=	2.7	Hz),	
128.7	(d,	J	=	1.5	Hz),	128.3,	128.1,	126.1	(d,	J	=	24.0	Hz),	124.8,	117.2	(d,	J	=	2.6	Hz),	109.6,	
107.6,	104.8,	96.5	(d,	J	=	19.9	Hz),	51.4	(d,	J	=	6.2	Hz),	38.0	(d,	J	=	30.0	Hz),	36.4,	34.0	ppm.	
19F	NMR	(300	MHz,	CDCl3)	δ	–128.6	ppm.	
FTIR	2936,	2794,	1612,	1494,	1446,	1370,	1310,	1213,	1100,	1026,	940	(NaCl/thin	film):	
cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C18H20FN2	[M+H]+:	283.1605,	found:	283.1603.	
	
	
	
A	 flame‐dried	 15	 mL	 round‐bottom	 flask	 was	 charged	 with	 sodium	 hydride	 (60%	
dispersion	in	oil,	7	mg,	182	µmol,	3.0	equiv)	and	DMF	(300	µL).	The	solution	was	cooled	to	
0	°C	and	a	solution	of	(+)‐2	(17	mg,	61	µmol)	in	DMF	(500	µL)	was	added	dropwise.	The	ice	
bath	was	removed	and	the	solution	was	allowed	to	warm	to	ambient	temperature	over	20	
min.	Methyl	iodide	(20	µL,	303	µmol,	5.0	equiv)	was	added	dropwise.	After	stirring	for	1.5	
h,	the	reaction	was	quenched	with	a	solution	of	H2O	and	saturated	aqueous	NH4Cl	(3:1	v/v	
ratio,	2	mL).	The	resulting	mixture	was	extracted	with	Et2O	(3	mL	x	4)	and	the	combined	
organic	extracts	were	dried	(Na2SO4),	 filtered,	and	concentrated	under	reduced	pressure.	
The	 crude	 residue	was	purified	by	 silica	 gel	 chromatography	 (2–7%	EtOAc/hexanes)	 to	
afford	(+)‐10	(18	mg,	>99%	yield)	as	a	yellow	viscous	oil.		
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The	same	procedure	was	performed	on	(–)‐2	(17	mg,	61	µmol)	to	afford	(–)‐10	(17.5	mg,	
98%	yield)	as	a	yellow	viscous	oil.		
(+)‐10:	
[α]D25	=	+131.6°	(c	=	0.90,	CHCl3).	
SFC:	97%	ee	(AD‐H	column:	12	min,	10%	i‐PrOH/CO2;	retention	time	=	4.5	min).	
(–)‐10:	
[α]D25	=	–139.9°	(c	=	0.875,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	10%	i‐PrOH/CO2;	retention	time	=	3.5	min).	
	
TLC	Rf	=	0.63	in	17%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(500	MHz,	CDCl3)	δ	7.45	(br	s,	2H),	7.38	–	7.32	(m,	2H),	7.33	–	7.26	(m,	1H),	7.23	
(ddd,	J	=	7.8,	7.4,	1.3	Hz,	1H),	7.12	(ddd,	J	=	7.3,	1.4,	0.5	Hz,	1H),	6.69	(td,	J	=	7.3,	1.0	Hz,	1H),	
6.44	(d,	J	=	7.8	Hz,	1H),	3.08	–	2.98	(m,	1H),	2.82	(s,	3H),	2.64	(s,	3H),	2.55	(ddd,	J	=	11.8,	8.6,	
4.7	Hz,	1H),	2.51	–	2.42	(m,	1H),	2.42	(s,	3H),	2.16	–	2.07	(m,	1H)	ppm.	
13C	NMR	(126	MHz,	CDCl3)	δ	152.9,	137.8,	129.9,	129.6,	127.9,	127.7,	127.5,	124.8,	116.4,	
104.1,	96.3,	96.2,	52.4,	51.5,	37.6,	36.5,	33.8	ppm.	
FTIR	(NaCl/thin	film):	3386,	3053,	2934,	2792,	1607,	1495,	1446,	1373,	1310,	1261,	1217,	
1161,	1119,	1039,	972	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C19H23N2O	[M+H]+:	295.1805,	found:	295.1811.	
	
	
	
A	 flame‐dried	25	mL	round‐bottom	 flask	was	charged	with	 (+)‐2	 (37	mg,	132	µmol)	and	
DMF	(1.6	mL).	The	solution	was	cooled	to	0	°C	and	a	solution	of	N‐iodosuccinimide	(39	mg,	
172	µmol,	1.3	equiv)	in	DMF	(1	mL)	was	added	dropwise	over	2	min.	After	stirring	for	10	
min,	 the	 reaction	 was	 allowed	 to	 warm	 to	 room	 temperature	 over	 20	 min,	 and	 then	
warmed	 to	 50	 °C	 and	 stirred	 for	 3	 h.	 After	 this	 time,	 the	 reaction	was	 cooled	 to	 room	
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temperature	and	quenched	with	a	2:1	solution	of	H2O	and	10	wt%	Na2S2O3	(aq)	(5	mL).	The	
resulting	mixture	was	extracted	with	Et2O	(3	mL	x	4).	The	combined	organic	extracts	were	
washed	with	brine	(1.5	mL	x	1)	and	then	dried	(MgSO4),	filtered,	and	concentrated	under	
reduced	pressure.	The	 crude	 residue	was	purified	by	 silica	 gel	 chromatography	 (5–15%	
EtOAc/hexanes)	to	afford	(–)‐11	(40	mg,	75%	yield)	as	a	viscous	yellow	oil.		
	
	
The	same	procedure	was	performed	on	(–)‐2	(40	mg,	143	µmol)	to	afford	(+)‐11	(42.7	mg,	
74%	yield)	as	a	viscous	yellow	oil.		
(–)‐11:	
[α]D25	=	–7.2°	(c	=	1.00,	CHCl3).	
SFC:	96.4%	ee	(AD‐H	column:	12	min,	25%	i‐PrOH/CO2;	retention	time	=	8.6	min).	
(+)‐11:	
[α]D25	=	+6.3°	(c	=	1.00,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	25%	i‐PrOH/CO2;	retention	time	=	6.7	min).	
	
TLC	Rf	=	0.42	in	15%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CDCl3)	δ	7.53	–	7.43	(m,	2H),	7.43	–	7.35	(m,	2H),	7.32	(tt,	J	=	7.1,	1.5	Hz,	
1H),	6.23	(d,	J	=	9	Hz,	1H),	3.04	(ddd,	J	=	9.2,	5.3,	2.4	Hz,	1H),	2.73	(s,	3H),	2.68	–	2.51	(m,	
1H),	2.47	 (s,	3H),	2.28	–	2.16	 (m,	2H),	1.37	 (br	s,	1H)	ppm.	Note:	A	 total	of	6H	aromatic	
protons	observed	with	relaxation	delay	=	1	sec;	8H	expected	if	relaxation	delay	is	>	5	sec.	
13C	NMR	 (101	MHz,	CDCl3)	 δ	152.2,	138.5,	136.8,	133.7,	132.7,	129.1,	128.4,	106.6,	98.7,	
90.3,	51.5,	40.7,	36.7,	34.5	ppm.	
FTIR	3540,	3448,	3059,	2935,	2794,	1596,	1487,	1446,	1367,	1267,	1164,	1106,	1028,	986	
(NaCl/thin	film):	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C18H20IN2O	[M+H]+:	407.0615,	found:	407.0603.	
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A	1	dram	 vial	 containing	 (–)‐11	 (30	mg,	74	µmol)	 and	1,10‐phenanthroline	 (3.5	mg,	20	
µmol,	0.25	equiv)	was	 transferred	 to	a	nitrogen	 filled	glovebox	and	charged	with	KF	 (14	
mg,	236	µmol,	3.0	equiv),	CuI	(3.8	mg,	20	µmol,	0.25	equiv),	and	DMSO	(390	µL).	The	vial	
was	 removed	 from	 the	 glovebox	 and	 trimethyl	borate	 (26	µL,	236	µmol,	3.0	 equiv)	 and	
TMSCF3	 (35	µL,	236	µmol,	3.0	 equiv)	were	 added.	The	 vial	was	 flushed	with	 argon	 and	
sealed	with	a	Teflon	cap	and	then	stirred	at	65	°C	for	24	h.	The	reaction	mixture	was	then	
cooled	 to	 room	 temperature	 and	water	 (0.5	mL)	was	 added.	 The	 solution	was	 filtered	
through	 a	 small	 pad	 of	 Celite	 and	 rinsed	 copiously	with	 Et2O	 (5	mL).	The	 solution	was	
washed	with	water	(2.5	mL)	and	the	aqueous	layer	was	extracted	with	Et2O	(4	mL	x	3).	The	
combined	organic	 solutions	were	washed	with	brine	 (2	mL	x	1),	dried	 (MgSO4),	 filtered,	
and	concentrated	under	reduced	pressure.	The	crude	residue	was	dissolved	 in	THF	 (790	
µL)	and	TBAF	(1.0	M	in	THF,	20	µL,	197	µmol,	2.5	equiv)	was	added	dropwise.	The	solution	
was	 stirred	 for	 1.5	 h	 and	 then	 quenched	 with	 brine	 (2	mL).	 The	mixture	 was	 stirred	
vigorously	 for	 20	min	 and	 then	 extracted	with	 Et2O	 (4	mL	 x	 3).	 The	 combined	 organic	
solutions	 were	 dried	 (MgSO4),	 filtered,	 and	 concentrated	 under	 reduced	 pressure.	 The	
resulting	 yellow	 oil	was	 purified	 by	 silica	 gel	 chromatography	 (0–2%	 EtOAc/CH2Cl2)	 to	
afford	(+)‐12	(11.0	mg,	43%	yield)	as	a	yellow	solid	and	recovered	(–)‐11	(16.5	mg,	56%	
yield	RSM)	as	a	yellow	solid.		
	
	
The	same	procedure	was	performed	on	(+)‐11	(32	mg,	79	µmol)	to	afford	(–)‐12	(13.0	mg,	
47%	yield)	as	a	yellow	solid	and	recovered	(+)‐11	(12.5	mg,	39%	yield	RSM)	as	a	yellow	
solid.		
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(+)‐12:	
[α]D25	=	+7.5°	(c	=	0.65,	CHCl3).	
SFC:	98%	ee	(AD‐H	column:	12	min,	10%	i‐PrOH/CO2;	retention	time	=	9.5	min).	
(–)‐12:	
[α]D25	=	–13.1°	(c	=	0.62,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	10%	i‐PrOH/CO2;	retention	time	=	6.5	min).	
	
TLC	Rf	=	0.28	in	10%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CDCl3)	δ	7.50	–	7.44	(m,	2H),	7.44	–	7.30	(m,	3H),	6.43	(d,	J	=	8.3	Hz,	1H),	
3.14	–	2.99	(m,	1H),	2.80	(s,	3H),	2.62	–	2.53	(m,	1H),	2.50	(s,	3H),	2.26	(dd,	J	=	7.8,	3.1	Hz,	
2H),	1.40	 (br	s,	1H)	ppm.	Note:	A	 total	of	6H	aromatic	protons	observed	with	 relaxation	
delay	=	1	sec;	8H	expected	if	relaxation	delay	is	>	5	sec.	
13C	NMR	(101	MHz,	CDCl3)	δ	154.82,	136.58,	131.09,	129.14,	128.58,	127.94	(q,	J	=	3.8	Hz),	
126.59,	123.91,	121.51	(q,	J	=	3.6	Hz),	103.51,	99.04,	90.15,	51.46,	40.71,	36.66,	34.38	ppm.	
19F	NMR	(300	MHz,	CDCl3)	δ	–60.4	ppm.	
FTIR	3436,	3058,	2934,	2797,	1703,	1622,	1516,	1446,	1383,	1326,	1271,	1108	(NaCl/thin	
film):	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C19H20F3N2O	[M+H]+:	349.1522,	found:	349.1504.	
	
	
	
A	 flame‐dried	25	mL	round‐bottom	 flask	was	charged	with	 (+)‐2	 (63	mg,	225	µmol)	and	
DMF	(4	mL).	The	solution	was	cooled	to	0	°C	and	a	solution	of	N‐bromosuccinimide	(40	mg,	
222	µmol,	0.99	equiv)	 in	DMF	(1	mL)	was	added	dropwise	over	10	min.	After	stirring	for	
0.5	h,	a	 solution	of	H2O	and	10	wt%	Na2S2O3	 (aq)	 (6:1	v/v	 ratio,	6	mL)	was	added.	The	
resulting	mixture	was	extracted	with	Et2O	(2	mL	x	4)	and	 the	combined	organic	extracts	
were	dried	(MgSO4),	filtered,	and	concentrated	under	reduced	pressure.	The	crude	residue	
was	purified	by	 silica	gel	 chromatography	 (5–15%	EtOAc/hexanes)	 to	 afford	 (+)‐13	 (77	
mg,	96%	yield)	as	a	light‐yellow	foam.		
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The	same	procedure	was	performed	on	(–)‐2	(63	mg,	225	µmol)	to	afford	(–)‐13	(75.5	mg,	
94%	yield)	as	a	white	foam.		
(+)‐13:	
[α]D25	=	+3.9°	(c	=	1.00,	CHCl3).	
SFC:	98%	ee	(AD‐H	column:	12	min,	20%	i‐PrOH/CO2;	retention	time	=	8.6	min).	
(–)‐13:	
[α]D25	=	–4.4°	(c	=	1.00,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	20%	i‐PrOH/CO2;	retention	time	=	9.6	min).	
	
TLC	Rf	=	0.26	in	10%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CDCl3)	δ	7.39	(br	t,	J	=	7.4	Hz,	2H),	7.36	–	7.27	(m,	3H),	6.30	(d,	J	=	8.2	
Hz,	1H),	3.14	–	2.98	(m,	1H),	2.73	(s,	3H),	2.66	–	2.51	(m,	1H),	2.47	(s,	3H),	2.30	–	2.18	(m,	
2H),	1.38	(br	s,	1	H)	ppm.	Note:	A	 total	of	6H	aromatic	protons	observed	with	relaxation	
delay	=	1	sec;	8H	expected	if	relaxation	delay	is	>	5	sec.	
13C	NMR	(101	MHz,	CDCl3)	δ	151.6,	136.8,	133.1,	132.6,	129.0,	128.4,	127.1,	108.2,	105.7,	
98.9,	90.3,	51.5,	40.7,	36.7,	34.6	ppm.	
FTIR	3544,	3445,	3057,	2937,	2794,	1601,	1491,	1445,	1368,	1265,	1162,	1106,	1028,	987,	
938	(NaCl/thin	film):	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C18H20BrN2O	[M+H]+:	359.0754,	found:	359.9767.	
	
	
	
A	2	dram	vial	containing	(+)‐13	(20	mg,	56	µmol)	was	charged	with	CuI	(21	mg,	835	µmol,	
2.0	equiv)	 in	a	nitrogen‐filled	glovebox.	The	vial	was	removed	from	the	glovebox	and	dry	
DMF	(560	µL)	was	added	followed	by	a	freshly	prepared	solution	of	NaOMe	in	MeOH	(4.0	
M,	210	µL,	15.0	equiv)	prepared	by	slowly	adding	Na	portion	wise	to	dry	MeOH	and	stirring	
overnight.	The	vial	was	sealed	under	argon	with	a	Teflon	cap	and	stirred	at	120	°C	for	2	h.	
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The	reaction	mixture	was	then	cooled	to	room	temperature	and	filtered	through	a	pad	of	
Celite	and	rinsed	copiously	with	Et2O	(12	mL).	The	organic	filtrate	was	washed	with	water	
(3	mL	 x	 1)	 and	 the	 aqueous	 layer	was	 extracted	with	 Et2O	 (2	mL	 x	 3).	 The	 combined	
organic	solutions	were	washed	with	brine	(2	mL	x	1),	and	then	dried	(MgSO4),	filtered,	and	
concentrated	 under	 reduced	 pressure.	 The	 crude	 residue	 was	 purified	 by	 silica	 gel	
chromatography	(10–25%	EtOAc/hexanes)	to	afford	(+)‐14	(15	mg,	86%	yield)	as	a	 light	
yellow	oil.		
	
	
The	same	procedure	was	performed	on	(–)‐13	(20	mg,	56	µmol)	to	afford	(–)‐14	(15.3	mg,	
88%	yield)	as	a	light	yellow	oil.		
(+)‐14:	
[α]D25	=	+1.9°	(c	=	0.75,	CHCl3).	
SFC:	97%	ee	(AD‐H	column:	12	min,	20%	i‐PrOH/CO2;	retention	time	=	8.2	min).	
(–)‐14:	
[α]D25	=	–4.0°	(c	=	0.77,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	20%	i‐PrOH/CO2;	retention	time	=	7.5	min).	
	
TLC	Rf	=	0.19	in	20%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CDCl3)	δ	7.38	(br	t,	J	=	7.4	Hz,	2H),	7.31	(ddd,	J	=	8.5,	7.0,	1.6	Hz,	1H),	
6.90	(d,	J	=	2.6	Hz,	1H),	6.81	(dd,	J	=	8.4,	2.7	Hz,	1H),	6.34	(d,	J	=	8.5	Hz,	1H),	3.76	(s,	3H),	
3.12	–	2.97	(m,	1H),	2.72	(s,	3H),	2.66	–	2.53	(m,	1H),	2.47	(s,	3H),	2.30	–	2.20	(m,	2H),	1.38	
(br	s,	1H)	ppm.	Note:	A	total	of	6H	aromatic	protons	observed	with	relaxation	delay	=	1	sec;	
8H	expected	if	relaxation	delay	is	>	5	sec.	
13C	NMR	(101	MHz,	CDCl3)	δ	152.3,	147.3,	137.5,	131.9,	128.9,	128.1,	115.5,	110.6,	104.4,	
98.9,	90.9,	56.3,	51.7,	40.8,	36.7,	35.1	ppm.	
FTIR	 3470,	 2936,	 2816,	 1622,	 1598,	 1504,	 1446,	 1361,	 1274,	 1216,	 1114,	 1027,	 988	
(NaCl/thin	film):	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C19H23N2O2	[M+H]+:	311.1754,	found:	311.1744.	
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A	2	dram	vial	containing	(+)‐13	(15	mg,	42	µmol)	was	charged	with	DavePhos	(2.5	mg,	6	
µmol,	0.15	equiv)	 in	a	nitrogen‐filled	glovebox.	The	vial	was	 removed	 from	 the	glovebox	
and	1,4‐dioxane	(300	µL),	Pd2(dba)3	(3.8	mg,	4	µmol,	0.10	equiv),	NaOt‐Bu	(8	mg,	84	µmol,	
2.0	equiv),	and	morpholine	 (10	µL,	13	µmol,	3.0	equiv)	were	added.	The	vial	was	sealed	
under	argon	with	a	Teflon	cap	and	stirred	at	100	°C	for	4	h.	The	reaction	mixture	was	then	
cooled	to	room	temperature	and	diluted	with	CH2Cl2	(2	mL).	The	solution	was	washed	with	
water	 (2	 mL	 x	 1)	 and	 the	 aqueous	 layer	 was	 extracted	 with	 CH2Cl2	 (2	 mL	 x	 3).	 The	
combined	organic	extracts	were	dried	(Na2SO4),	filtered,	and	concentrated	under	reduced	
pressure.	 The	 crude	 residue	 was	 purified	 by	 silica	 gel	 chromatography	 (25–60%	
EtOAc/CH2Cl2),	and	the	isolated	fractions	purified	again	by	silica	gel	chromatography	(33–
75%	EtOAc/hexanes),	to	give	(–)‐15	(12.3	mg,	80%	yield)	as	a	yellow	oil.		
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NBr
O
morpholine
10 mol % Pd2(dba)3
15 mol % DavePhos
NaOt-Bu
1,4-dioxane, 100 °C
85% yield 	
The	same	procedure	was	performed	on	(–)‐13	(20	mg,	56	µmol)	to	afford	(+)‐15	(13.0	mg,	
85%	yield)	as	a	yellow	oil.		
(–)‐15:	
[α]D25	=	–13.1°	(c	=	0.62,	CHCl3).	
SFC:	98%	ee	(AD‐H	column:	12	min,	25%	i‐PrOH/CO2;	retention	time	=	8.0	min).	
(+)‐15:	
[α]D25	=	+7.5°	(c	=	0.65,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	25%	i‐PrOH/CO2;	retention	time	=	6.5	min).	
	
TLC	Rf	=	0.32	in	60%	EtOAc/hexanes	(UV,	KMnO4).	
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1H	NMR	(400	MHz,	CDCl3)	δ	7.62	–	7.27	(m,	4H),	6.98	(br	d,	J	=	2.5	Hz,	1H),	6.85	(br	d,	J	=	
8.4	Hz,	1H),	6.36	(d,	J	=	8.4	Hz,	1H),	3.85	(t,	J	=	4.7	Hz,	4H),	3.04	(d,	J	=	4.6	Hz,	5H),	2.72	(s,	
3H),	2.65	–	2.52	(m,	1H),	2.46	(s,	3H),	2.34	–	2.15	(m,	2H),	1.37	(br	s,	1H)	ppm.	Note:	A	total	
of	7H	aromatic	protons	observed	with	relaxation	delay	=	1	sec;	8H	expected	 if	relaxation	
delay	is	>	5	sec.	
13C	NMR	(101	MHz,	CDCl3)	δ	147.8,	143.7,	137.5,	131.9,	128.9,	128.2,	118.7,	114.5,	104.4,	
98.9,	91.0,	67.3,	51.8,	51.6,	40.7,	36.7,	34.9	ppm.	
FTIR	 3407,	 2933,	 2856,	 2815,	 1622,	 1503,	 1446,	 1360,	 1296,	 1257,	 1215,	 1118,	 1028	
(NaCl/thin	film):	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C22H28N3O2	[M+H]+:	366.2176,	found:	366.2181.	
	
Scheme	S1.	Synthesis	of	Aryl	Bromide	16.	
	
 
	
Synthesis	of	Aryl	Bromide	16	
	
	
On	a	benchtop,	a	10–20	mL	microwave	vial	was	charged	with	4	(600	mg,	1.95	mmol),	DMF	
(7.8	mL),	 2‐nitrobenzoic	 acid	 (488	mg,	 2.92	mmol,	 1.5	 equiv),	 1‐bromo‐4‐iodobenzene	
(2.20	g,	7.78	mmol,	4.0	equiv),	Pd(OAc)2	(22	mg,	97	µmol,	0.05	equiv),	and	then	AgBF4	(568	
mg,	2.92	mmol,	1.5	equiv).	A	magnetic	vane	stirbar	was	added	and	the	reaction	was	flushed	
with	 argon	 and	 capped	 using	 a	microwave	 vial	 crimper.	 The	 solution	was	 then	 stirred	
vigorously	(660	rpm)	 in	the	dark	 for	40	min.	The	black‐brown	opaque	solution	was	then	
subjected	to	microwave	irradiation	using	a	Biotage	microwave	reactor	for	4	min	at	150	°C	
(stirred	 at	 660	 rpm).	The	 reaction	was	 filtered	 over	 a	 short	 plug	 of	 Celite,	 eluting	with	
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EtOAc	 (40	 mL).	 The	 filtrate	 was	 washed	 with	 saturated	 aqueous	 NH4Cl	 (15	 mL	 x	 2),	
saturated	aqueous	NaHCO3	(15	mL	x	2),	and	brine	(15	mL	x	2)	and	the	organic	 layer	was	
dried	(MgSO4),	filtered,	and	concentrated	under	reduced	pressure.	The	crude	residue	was	
purified	by	silica	gel	chromatography	(5–25%	EtOAc/hexanes)	to	afford	SI‐2	(606	mg,	67%	
yield)	as	a	yellow	foam.		
TLC	Rf	=	0.33	in	15%	EtOAc/hexanes	(UV,	KMnO4).	
1H	 NMR	 (400	MHz,	 CDCl3,	 compound	 exists	 as	 a	 6.6:1	mixture	 of	 rotamers,	 the	major	
rotamer	is	designated	by	*,	minor	rotamer	designated	by	§)	7.65	(d,	J	=	7.9	Hz,	1H*,	1H§),	
7.61	–	7.54	(m,	3H*),	7.54	–	7.47	(m,	3H§),	7.41	–	7.27	(m,	6H*,	6H§),	7.25	–	7.20	(m,	2H*,	
2H§),	7.16	(t,	J	=	7.6	Hz,	1H*),	7.15	–	7.07	(br	s,	1H§),	5.04	(s,	2H*,	2H§),	4.71	(t,	J	=	6.2	Hz,	
1H*),	4.50	(br	s,	1H§),	3.56	(s,	3H*,	3H§),	3.42	(q,	J	=	6.7	Hz,	2H*),	3.41	–	3.31	(br	s,	2H§),	
2.91	(t,	J	=	6.9	Hz,	2H*,	2H§)	ppm.	
13C	NMR	(101	MHz,	CDCl3;	compound	exists	as	a	6.6:1	mixture	of	rotamers,	only	the	major	
rotamer	 is	 reported)	156.3,	137.6,	137.4,	136.8,	132.3,	131.9,	130.7,	128.6,	128.2,	128.2,	
127.5,	122.8,	122.3,	119.8,	119.1,	110.2,	109.6,	66.6,	41.8,	31.0,	25.3	ppm.	
FTIR	(NaCl/thin	film):	3426,	3342,	3052,	2940,	1714,	1514,	1470,	1360,	1234,	1133,	1072,	
1009,	908	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C25H24BrN2O2	[M+H]+	463.1016,	found:	463.0994.	
	
	
A	 flame‐dried	250	mL	 round‐bottom	 flask	was	 charged	with	 SI‐2	 (495	mg,	1.07	mmol),	
MeCN	 (11	mL),	and	activated	3Å	molecular	 sieve	pellets	 (673	mg,	1.3	x	mass	of	SI‐2).	A	
solution	of	N‐chlorosuccinimide	 (179	mg,	1.34	mmol,	1.26	equiv)	 in	MeCN	 (22	mL)	was	
added	dropwise	over	5	min.	The	 flask	was	wrapped	 in	aluminum	 foil	and	 stirred	 in	 the	
dark	 for	3	h.	TLC	analysis	 indicated	 consumption	of	 starting	material	 (Rf	of	 the	putative	
chloride	 intermediate	=	0.61;	33%	EtOAc/hexanes,	UV,	KMnO4).	Water	(22	mL)	was	then	
added	dropwise	 and	 the	 reaction	was	 stirred	 for	1	h.	The	 reaction	mixture	was	 filtered	
through	a	Celite	pad	and	rinsed	copiously	with	EtOAc	(30	mL).	A	2:1	mixture	of	saturated	
aqueous	NaHCO3/brine	(20	mL)	was	added	and	the	layers	were	partitioned	in	a	separatory	
funnel.	The	aqueous	layer	was	extracted	with	EtOAc	(30	mL	x	3)	and	the	combined	organic	
extracts	 were	 dried	 (Na2SO4),	 filtered,	 and	 concentrated	 under	 reduced	 pressure.	 The	
 
 S28 
crude	 residue	 was	 purified	 by	 silica	 gel	 chromatography	 (10–25%	 EtOAc/hexanes)	 to	
afford	(±)‐SI‐3	(410	mg,	80%	yield)	as	a	yellow	foam.		
TLC	Rf	=	0.49	in	33%	EtOAc/hexanes	(UV,	KMnO4).	
1H	 NMR	 (500	MHz,	 CDCl3,	 compound	 exists	 as	 a	 1.2:1	mixture	 of	 rotamers,	 the	major	
rotamer	 is	designated	by	*,	minor	rotamer	designated	by	§)	7.56	–	7.05	(m,	10H*,	10H§),	
6.87	–	6.73	(m,	2H*,	2H§),	6.57	(d,	J	=	7.9	Hz,	1H*),	6.51	(d,	J	=	8.1	Hz,	1H§),	5.22	–	4.97	(m,	
2H*,	1H§),	4.81	(d,	 J	=	12.2	Hz,	1H§),	4.08	–	3.87	(m,	1H*,	1H§),	3.26	(td,	 J	=	11.2,	6.1	Hz,	
1H*),	3.17	(td,	J	=	11.7,	5.8	Hz,	1H§),	3.00	(s,	3H*),	2.75	(s,	3H§),	2.53	–	2.35	(m,	2H*),	2.21	
(dddd,	J	=	13.6,	10.1,	6.6,	2.9	Hz,	2H§),	1.51	(br	s,	1H*,	1H§)	ppm.	
13C	NMR	(125	MHz,	CDCl3;	compound	exists	as	a	1.2:1	mixture	of	rotamers)	154.9,	154.6,	
151.1,	 150.9,	 136.7,	 136.3,	 135.5,	 135.3,	 133.4,	 131.9,	 131.8,	 131.1,	 129.3,	 128.6,	 128.4,	
128.2,	128.1,	128.1,	128.0,	127.9,	123.8,	122.7,	122.4,	118.6,	118.2,	106.9,	106.8,	93.9,	93.2,	
90.0,	88.9,	67.3,	67.0,	46.4,	46.3,	34.3,	33.8,	31.9,	31.3	ppm.	
FTIR	(NaCl/thin	film):	3405,	3053,	3032,	2890,	1694,	1609,	1488,	1394,	1348,	1185,	1119,	
1001	cm‐1.	
HRMS	(TOF‐ESI,	m/z)	calc’d	for	C25H24BrN2O3	[M+H]+	479.0965,	found	479.0979.	
	
 	
Preparative	chiral	SFC	resolution:	Carbamate	(±)‐SI‐3	(240	mg)	was	dissolved	in	a	minimal	
amount	of	 IPA	(~4	mL).	This	solution	of	racemic	compound	was	resolved	by	preparative	
chiral	SFC	using	serial	 injections	(isocratic:	45%	 i‐PrOH/CO2)	to	afford	(–)‐SI‐3	(118	mg)	
and	(+)‐SI‐3	(107	mg)	as	yellow	foams.		
(+)‐SI‐3:	
[α]D25	=	+269.1°	(c	=1.00,	CHCl3).	
SFC:	97%	ee	(AD‐H	column:	12	min,	35%	i‐PrOH/CO2;	retention	time	=	8.4	min).	
(–)‐SI‐3:	
[α]D25	=	–253.8°	(c	=	1.00,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	35%	i‐PrOH/CO2;	retention	time	=	6.8	min).	
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Chiral	SFC	trace	of	(±)‐SI‐3	(35%	i‐PrOH/CO2): 	
	
	
Chiral	SFC	trace	of	(+)‐SI‐3	(35%	i‐PrOH/CO2):	
	
	
Chiral	SFC	trace	of	(–)‐SI‐3	(35%	i‐PrOH/CO2): 	
	
	
(±)‐SI‐3 
(+)‐SI‐3 
(–)‐SI‐3 
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A	25	mL	round‐bottom	flask	containing	(+)‐SI‐3	(31	mg,	65	µmol)	was	charged	with	EtOH	
(0.8	mL)	and	6	N	aqueous	solution	of	potassium	hydroxide	(540	µL).	The	flask	was	sealed	
under	argon	and	heated	 to	80	 °C.	After	 stirring	 for	76	h,	 the	 red	 solution	was	 cooled	 to	
room	temperature.	The	crude	mixture	was	filtered	through	Celite	and	rinsed	with	EtOAc	(5	
mL).	The	combined	organic	filtrates	were	washed	with	water	(2	mL)	and	the	aqueous	layer	
was	extracted	with	EtOAc	(3	mL	x	3).	The	combined	organics	were	washed	with	brine	(2	
mL,	x	1)	and	then	dried	(Na2SO4),	filtered,	and	concentrated	under	reduced	pressure.	The	
crude	 residue	 was	 purified	 by	 silica	 gel	 chromatography	 (10–33%	 EtOAc/hexanes)	 to	
afford	(+)‐SI‐4	(14	mg,	64%	yield)	as	an	amber	yellow	oil.		
	
	
The	same	procedure	was	performed	on	(–)‐SI‐3	(45	mg,	94	µmol)	to	afford	(–)‐SI‐4	(17.5	
mg,	54%	yield)	as	a	pale‐yellow	oil.		
(+)‐SI‐4:	
[α]D25	=	+39.6°	(c	=	0.70,	MeOH).	
SFC:	95%	ee	(AD‐H	column:	12	min,	30%	i‐PrOH/CO2;	retention	time	=	8.3	min).	
(–)‐SI‐4:	
[α]D25	=	–43.3°	(c	=	0.875,	MeOH).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	30%	i‐PrOH/CO2;	retention	time	=	5.7	min).	
	
TLC	Rf	=	0.28	in	30%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CD3CN)	δ	7.49	(d,	J	=	8.8	Hz,	2H),	7.34	(d,	J	=	8.6	Hz,	2H),	7.19	–	7.11	(m,	
2H),	6.63	(td,	J	=	7.4,	1.0	Hz,	1H),	6.43	(dd,	J	=	8.4,	1.0	Hz,	1H),	3.11	(ddd,	J	=	9.3,	5.3,	3.2	Hz,	
1H),	2.80	(br	s,	1H),	2.70	–	2.62	(m,	1H),	2.57	(s,	3H),	2.20	–	2.10	(m,	2H)	ppm.	Note:	One	of	
the	N–H/O–H	protons	was	not	observed	under	these	conditions.	
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13C	NMR	(101	MHz,	CD3CN)	δ	152.5,	140.7,	132.1,	131.7,	131.3,	130.6,	124.7,	121.8,	117.6,	
105.3,	94.5,	90.4,	43.8,	42.6,	28.6	ppm.	
FTIR	3363,	3053,	2932,	2856,	1608,	1494,	1374,	1306,	1205,	1120,	1071	(NaCl/thin	film):	
cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C17H18BrN2O	[M+H]+:	345.0597,	found:	345.0613.	
	
 	
A	1	dram	vial	containing	(+)‐SI‐4	(14	mg,	41	µmol)	was	charged	with	MeOH	(340	µL)	and	
CH2O	(37	wt%	in	H2O,	45	µL).	The	vial	was	sealed,	wrapped	with	aluminum	foil,	and	stirred	
at	50	°C	for	3	h.	The	solution	was	cooled	to	0	°C	and	NaBH4	(9	mg,	243	µmol,	6.0	equiv)	was	
added.	The	reaction	was	allowed	to	warm	to	ambient	temperature	over	10	min	and	then	
covered	with	aluminum	 foil	and	heated	at	50	 °C.	After	 stirring	 for	5	h,	 the	 reaction	was	
cooled	 to	 room	 temperature	and	quenched	with	H2O	 (2	mL).	The	mixture	was	extracted	
with	EtOAc	(3	mL	x	4).	The	combined	organic	extracts	were	washed	with	brine	(2	mL	x	1),	
dried	(Na2SO4),	filtered,	and	concentrated	under	reduced	pressure.	The	crude	residue	was	
purified	by	 silica	gel	 chromatography	 (5–40%	EtOAc/hexanes)	 to	afford	 (+)‐16	 (9.5	mg,	
66%	yield)	as	a	yellow	oil.		
	
	
The	same	procedure	was	performed	on	 (–)‐SI‐4	 (17	mg,	49	µmol)	 to	afford	 (–)‐16	 (12.7	
mg,	72%	yield)	as	a	pale‐yellow	oil.		
(+)‐16:	
[α]D25	=	+6.5°	(c	=	0.475,	CHCl3).	
SFC:	96%	ee	(AD‐H	column:	12	min,	25%	i‐PrOH/CO2;	retention	time	=	7.6	min).	
(–)‐16:	
[α]D25	=	–4.3°	(c	=	0.635,	CHCl3).	
SFC:	>99%	ee	(AD‐H	column:	12	min,	25%	i‐PrOH/CO2;	retention	time	=	6.3	min).	
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TLC	Rf	=	0.25	in	10%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CDCl3)	δ	7.50	(d,	J	=	8.1	Hz,	2H),	7.22	(td,	J	=	7.0,	1.5	Hz,	2H),	6.71	(t,	J	=	
7.4	Hz,	1H),	6.42	(d,	J	=	8.0	Hz,	1H),	3.01	(br	s,	1H),	2.75	(s,	3H),	2.61	–	2.50	(m,	1H),	2.44	(s,	
3H),	2.32	–	2.19	(m,	2H),	1.37	(br	s,	1H)	ppm.	Note:	A	total	of	6H	aromatic	protons	observed	
with	relaxation	delay	=	1	sec;	8H	expected	if	relaxation	delay	is	>	5	sec.	
13C	NMR	(101	MHz,	CDCl3)	δ	152.4,	136.9,	132.0,	130.4,	130.2,	124.1,	122.3,	117.2,	104.3,	
97.8,	90.9,	51.6,	40.5,	36.6,	34.3	ppm.	
FTIR	3438,	3053,	2932,	2793,	1608,	1494,	1372,	1308,	1214,	1106,	1031	(NaCl/thin	film):	
cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C18H20BrN2O	[M+H]+:	359.0754,	found:	359.0771.	
	
 	
A	2	dram	vial	containing	(±)‐16	(8	mg,	22	µmol)	was	charged	with	CuI	(8.5	mg,	45	µmol,	2.0	
equiv)	in	a	nitrogen‐filled	glovebox.	The	vial	was	removed	from	the	glovebox	and	dry	DMF	
(400	µL)	and	a	 freshly	prepared	 solution	of	NaOMe	 in	MeOH	 (4.0	M,	84	µL,	15.0	equiv)	
were	added.	The	vial	was	flushed	with	argon	and	sealed	with	a	Teflon	cap	and	then	stirred	
at	120	°C	for	1.5	h.	The	reaction	mixture	was	then	cooled	to	room	temperature	and	filtered	
through	 a	pad	of	Celite	 and	 rinsed	 copiously	with	Et2O	 (5	mL).	The	organic	 filtrate	was	
washed	with	water	(2	mL	x	1)	and	the	aqueous	layer	was	extracted	with	Et2O	(3	mL	x	3).	
The	 combined	 organic	 solutions	 were	 washed	 with	 brine	 (2	 mL	 x	 1),	 and	 then	 dried	
(MgSO4),	 filtered,	 and	 concentrated	 under	 reduced	 pressure.	 The	 crude	 residue	 was	
purified	by	silica	gel	chromatography	(10–25%	EtOAc/hexanes)	to	afford	(±)‐SI‐5	(5.9	mg,	
85%	yield)	as	a	yellow	oil.		
TLC	Rf	=	0.38	in	25%	EtOAc/hexanes	(UV,	KMnO4).	
1H	NMR	(400	MHz,	CDCl3)	δ	7.27	–	7.16	(m,	2H),	6.91	(d,	J	=	7.9	Hz,	2H),	6.69	(td,	J	=	7.4,	1.0	
Hz,	1H),	6.41	(d,	J	=	7.9	Hz,	1H),	3.81	(s,	3H),	3.01	(ddd,	J	=	8.3,	5.2,	2.3	Hz,	1H),	2.75	(s,	3H),	
2.61	–	2.51	(m,	1H),	2.46	(s,	3H),	2.29	–	2.20	(m,	2H),	1.37	(br	s,	1H)	ppm.	Note:	A	total	of	
6H	 aromatic	 protons	 observed	with	 relaxation	 delay	 =	 1	 sec;	 8H	 expected	 if	 relaxation	
delay	is	>	5	sec.	
13C	NMR	(101	MHz,	CDCl3)	δ	159.5,	152.6,	130.9,	130.0,	129.2,	124.1,	116.9,	114.3,	104.1,	
98.3,	90.4,	55.4,	51.6,	40.6,	36.7,	34.4	ppm.	
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FTIR	(NaCl/thin	film):	3478,	3051,	2934,	2791,	1608,	1494,	1372,	1304,	1245,	1172,	1106,	
1031	cm‐1.	
HRMS	(TOF‐ESI,	m/z):	calc’d	for	C19H23N2O2	[M+H]+:	311.1754,	found:	311.1743.	
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5.	Absolute	Stereochemical	Assignment	of	(+)‐2,	(+)‐6,	and	(+)‐SI‐3		
	
Low‐temperature	 diffraction	 data	 (φ‐	 and	 ω‐scans)	were	 collected	 on	 a	Bruker	AXS	D8	
VENTURE	 KAPPA	 diffractometer	 coupled	 to	 a	 PHOTON	 II	 CPAD	 detector	 with	 Cu‐Kα	
radiation	(λ	=	1.54178	Å)	 from	a	 IµS	HB	micro‐focus	sealed	X‐ray	tube.	All	diffractometer	
manipulations,	including	data	collection,	integration,	and	scaling	were	carried	out	using	the	
Bruker	 APEXII	 software.7	 Absorption	 corrections	 were	 applied	 using	 SADABS.8	 The	
structure	was	solved	by	intrinsic	phasing	using	SHELXT9	and	refined	against	F2	on	all	data	
by	full‐matrix	least	squares	with	SHELXL‐20149	using	established	refinement	techniques.10	
All	non‐hydrogen	atoms	were	refined	anisotropically.	Unless	otherwise	noted,	all	hydrogen	
atoms	were	included	into	the	model	at	geometrically	calculated	positions	and	refined	using	
a	riding	model.	The	isotropic	displacement	parameters	of	all	hydrogen	atoms	were	fixed	to	
1.2	 times	 the	U	 value	 of	 the	 atoms	 they	 are	 linked	 to	 (1.5	 times	 for	methyl	 groups	 and	
hydroxyl	 groups).	 Absolute	 configuration	 was	 determined	 by	 anomalous	 dispersion.11	
Graphical	 representation	 of	 the	 structures	with	 50%	 probability	 thermal	 ellipsoids	was	
generated	using	Mercury	visualization	software.	
	
Single	crystal	X‐ray	diffraction	data	for	(+)‐2	
	
Figure	S3:	Structure	of	(+)‐2	with	50%	probability	anisotropic	displacement	ellipsoids.	
	
Special	Refinement	Details	for	(+)‐2	
Compound	(+)‐2	crystallizes	in	the	monoclinic	space	group	P1211	with	one	molecule	in	the	
asymmetric	unit.	The	coordinates	 for	 the	hydrogen	atom	bound	 to	O1	was	 located	 in	 the	
difference	Fourier	synthesis	and	refined	using	a	riding	model.	No	hydrogen	bond	acceptor	
was	found	for	O1.	Absolute	configuration	was	determined	by	anomalous	dispersion	(Flack	
=	‐0.01(5)).11	
	
Table	S1.	Crystal	data	and	structure	refinement	for	(+)‐2.	
Identification	code		 V18441	
Empirical	formula		 C18H20N2O	
Formula	weight		 280.36	
Temperature		 99.99	K	
Wavelength		 1.54178	Å	
Crystal	system		 Monoclinic	
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Space	group		 P	1	21	1	
Unit	cell	dimensions	 a	=	7.7914(9)	Å	 =	90°.	
	 b	=	8.3695(10)	Å	 =	96.991(3)°.	
	 c	=	11.3709(13)	Å	 =	90°.	
Volume	 735.98(15)	Å3	
Z	 2	
Density	(calculated)	 1.265	Mg/m3	
Absorption	coefficient	 0.620	mm‐1	
F(000)	 300	
Crystal	size	 0.30	x	0.22	x	0.16	mm3	
Theta	range	for	data	collection	 3.917	to	79.687°.	
Index	ranges	 ‐9<=h<=9,	‐10<=k<=10,	‐14<=l<=14	
Reflections	collected	 24278	
Independent	reflections	 3062	[R(int)	=	0.0517]	
Completeness	to	theta	=	67.679°	 100.0	%		
Absorption	correction	 Semi‐empirical	from	equivalents	
Max.	and	min.	transmission	 0.7543	and	0.6759	
Refinement	method	 Full‐matrix	least‐squares	on	F2	
Data	/	restraints	/	parameters	 3062	/	1	/	196	
Goodness‐of‐fit	on	F2	 1.044	
Final	R	indices	[I>2sigma(I)]	 R1	=	0.0296,	wR2	=	0.0781	
R	indices	(all	data)	 R1	=	0.0298,	wR2	=	0.0782	
Absolute	structure	parameter	 ‐0.01(5)	
Extinction	coefficient	 0.0170(17)	
Largest	diff.	peak	and	hole	 0.227	and	‐0.202	e.Å‐3	
	
Table	S2.	Atomic	coordinates	(	x	104)	and	equivalent	isotropic	displacement	parameters	(Å2x	103)	
for	v18441_a.	U(eq)	is	defined	as	one	third	of	the	trace	of	the	orthogonalized	Uij	tensor.	
________________________________________________________________________________		
	 x	 y	 z	 U(eq)	
________________________________________________________________________________		
O(1)	 4721(2)	 2843(1)	 1638(1)	 19(1)	
N(1)	 2689(2)	 5966(2)	 3084(1)	 16(1)	
N(2)	 3419(2)	 3554(2)	 4304(1)	 20(1)	
C(9)	 3841(2)	 6733(2)	 2445(1)	 14(1)	
C(6)	 6489(2)	 7834(2)	 1221(2)	 20(1)	
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C(5)	 6414(2)	 6214(2)	 1516(1)	 18(1)	
C(18)	 833(2)	 1899(2)	 2804(2)	 20(1)	
C(15)	 ‐585(2)	 3188(2)	 651(2)	 21(1)	
C(16)	 ‐1266(2)	 1789(2)	 1061(2)	 23(1)	
C(4)	 5094(2)	 5680(2)	 2120(1)	 14(1)	
C(14)	 766(2)	 3960(2)	 1332(2)	 18(1)	
C(7)	 5219(2)	 8880(2)	 1522(1)	 19(1)	
C(13)	 1484(2)	 3333(2)	 2420(1)	 16(1)	
C(2)	 2984(2)	 4204(2)	 3114(1)	 16(1)	
C(1)	 1035(2)	 6703(2)	 3215(2)	 22(1)	
C(3)	 4758(2)	 4012(2)	 2541(1)	 15(1)	
C(17)	 ‐545(2)	 1142(2)	 2135(2)	 24(1)	
C(8)	 3872(2)	 8348(2)	 2128(1)	 17(1)	
C(11)	 5240(2)	 3923(2)	 4667(2)	 23(1)	
C(12)	 6061(2)	 3443(2)	 3577(2)	 22(1)	
C(10)	 2297(2)	 4004(3)	 5187(2)	 27(1)	
________________________________________________________________________________		
	
Table	S3.		Bond	lengths	[Å]	and	angles	[°]	for	v18441_a.	
_____________________________________________________		
O(1)‐C(3)		 1.417(2)	
O(1)‐H(1)		 0.86(3)	
N(1)‐C(9)		 1.380(2)	
N(1)‐C(2)		 1.493(2)	
N(1)‐C(1)		 1.453(2)	
N(2)‐C(2)		 1.460(2)	
N(2)‐C(11)		 1.461(2)	
N(2)‐C(10)		 1.458(2)	
C(9)‐C(4)		 1.398(2)	
C(9)‐C(8)		 1.399(2)	
C(6)‐H(6)		 0.9500	
C(6)‐C(5)		 1.400(2)	
C(6)‐C(7)		 1.395(3)	
C(5)‐H(5)		 0.9500	
C(5)‐C(4)		 1.379(2)	
C(18)‐H(18)		 0.9500	
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C(18)‐C(13)		 1.394(2)	
C(18)‐C(17)		 1.391(3)	
C(15)‐H(15)		 0.9500	
C(15)‐C(16)		 1.389(3)	
C(15)‐C(14)		 1.388(2)	
C(16)‐H(16)		 0.9500	
C(16)‐C(17)		 1.390(3)	
C(4)‐C(3)		 1.509(2)	
C(14)‐H(14)		 0.9500	
C(14)‐C(13)		 1.396(2)	
C(7)‐H(7)		 0.9500	
C(7)‐C(8)		 1.396(2)	
C(13)‐C(2)		 1.515(2)	
C(2)‐C(3)		 1.607(2)	
C(1)‐H(1A)		 0.9800	
C(1)‐H(1B)		 0.9800	
C(1)‐H(1C)		 0.9800	
C(3)‐C(12)		 1.534(2)	
C(17)‐H(17)		 0.9500	
C(8)‐H(8)		 0.9500	
C(11)‐H(11A)		 0.9900	
C(11)‐H(11B)		 0.9900	
C(11)‐C(12)		 1.516(2)	
C(12)‐H(12A)		 0.9900	
C(12)‐H(12B)		 0.9900	
C(10)‐H(10A)		 0.9800	
C(10)‐H(10B)		 0.9800	
C(10)‐H(10C)		 0.9800	
	
C(3)‐O(1)‐H(1)	 109.6(19)	
C(9)‐N(1)‐C(2)	 111.35(13)	
C(9)‐N(1)‐C(1)	 119.91(14)	
C(1)‐N(1)‐C(2)	 123.54(14)	
C(2)‐N(2)‐C(11)	 106.90(13)	
C(10)‐N(2)‐C(2)	 116.78(14)	
C(10)‐N(2)‐C(11)	 113.20(14)	
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N(1)‐C(9)‐C(4)	 111.45(15)	
N(1)‐C(9)‐C(8)	 128.15(15)	
C(4)‐C(9)‐C(8)	 120.39(15)	
C(5)‐C(6)‐H(6)	 120.1	
C(7)‐C(6)‐H(6)	 120.1	
C(7)‐C(6)‐C(5)	 119.85(16)	
C(6)‐C(5)‐H(5)	 120.4	
C(4)‐C(5)‐C(6)	 119.25(15)	
C(4)‐C(5)‐H(5)	 120.4	
C(13)‐C(18)‐H(18)	 119.8	
C(17)‐C(18)‐H(18)	 119.8	
C(17)‐C(18)‐C(13)	 120.46(17)	
C(16)‐C(15)‐H(15)	 120.0	
C(14)‐C(15)‐H(15)	 120.0	
C(14)‐C(15)‐C(16)	 120.00(16)	
C(15)‐C(16)‐H(16)	 120.2	
C(15)‐C(16)‐C(17)	 119.55(16)	
C(17)‐C(16)‐H(16)	 120.2	
C(9)‐C(4)‐C(3)	 110.22(14)	
C(5)‐C(4)‐C(9)	 120.98(15)	
C(5)‐C(4)‐C(3)	 128.80(15)	
C(15)‐C(14)‐H(14)	 119.5	
C(15)‐C(14)‐C(13)	 120.92(16)	
C(13)‐C(14)‐H(14)	 119.5	
C(6)‐C(7)‐H(7)	 119.4	
C(6)‐C(7)‐C(8)	 121.26(16)	
C(8)‐C(7)‐H(7)	 119.4	
C(18)‐C(13)‐C(14)	 118.66(15)	
C(18)‐C(13)‐C(2)	 122.53(15)	
C(14)‐C(13)‐C(2)	 118.77(15)	
N(1)‐C(2)‐C(13)	 110.90(13)	
N(1)‐C(2)‐C(3)	 103.10(12)	
N(2)‐C(2)‐N(1)	 114.06(13)	
N(2)‐C(2)‐C(13)	 112.41(13)	
N(2)‐C(2)‐C(3)	 102.97(12)	
C(13)‐C(2)‐C(3)	 112.80(13)	
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N(1)‐C(1)‐H(1A)	 109.5	
N(1)‐C(1)‐H(1B)	 109.5	
N(1)‐C(1)‐H(1C)	 109.5	
H(1A)‐C(1)‐H(1B)	 109.5	
H(1A)‐C(1)‐H(1C)	 109.5	
H(1B)‐C(1)‐H(1C)	 109.5	
O(1)‐C(3)‐C(4)	 113.47(13)	
O(1)‐C(3)‐C(2)	 114.87(13)	
O(1)‐C(3)‐C(12)	 107.17(13)	
C(4)‐C(3)‐C(2)	 103.14(12)	
C(4)‐C(3)‐C(12)	 113.99(13)	
C(12)‐C(3)‐C(2)	 103.96(12)	
C(18)‐C(17)‐H(17)	 119.8	
C(16)‐C(17)‐C(18)	 120.36(17)	
C(16)‐C(17)‐H(17)	 119.8	
C(9)‐C(8)‐H(8)	 120.9	
C(7)‐C(8)‐C(9)	 118.23(15)	
C(7)‐C(8)‐H(8)	 120.9	
N(2)‐C(11)‐H(11A)	 111.4	
N(2)‐C(11)‐H(11B)	 111.4	
N(2)‐C(11)‐C(12)	 101.85(13)	
H(11A)‐C(11)‐H(11B)	 109.3	
C(12)‐C(11)‐H(11A)	 111.4	
C(12)‐C(11)‐H(11B)	 111.4	
C(3)‐C(12)‐H(12A)	 111.0	
C(3)‐C(12)‐H(12B)	 111.0	
C(11)‐C(12)‐C(3)	 103.85(13)	
C(11)‐C(12)‐H(12A)	 111.0	
C(11)‐C(12)‐H(12B)	 111.0	
H(12A)‐C(12)‐H(12B)	 109.0	
N(2)‐C(10)‐H(10A)	 109.5	
N(2)‐C(10)‐H(10B)	 109.5	
N(2)‐C(10)‐H(10C)	 109.5	
H(10A)‐C(10)‐H(10B)	 109.5	
H(10A)‐C(10)‐H(10C)	 109.5	
H(10B)‐C(10)‐H(10C)	 109.5	
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_____________________________________________________________		
Symmetry	transformations	used	to	generate	equivalent	atoms:		
		
Table	S4.		Anisotropic	displacement	parameters	(Å2x	103)	for	v18441_a.	The	anisotropic	
displacement	factor	exponent	takes	the	form:	‐22[	h2	a*2U11	+	...	+	2	h	k	a*	b*	U12	]	
______________________________________________________________________________		
	 U11	 U22		 U33	 U23	 U13	 U12	
______________________________________________________________________________		
O(1)	 22(1)		 14(1)	 22(1)		 ‐3(1)	 4(1)		 2(1)	
N(1)	 15(1)		 14(1)	 20(1)		 ‐2(1)	 4(1)		 ‐1(1)	
N(2)	 22(1)		 22(1)	 16(1)		 2(1)	 1(1)		 ‐4(1)	
C(9)	 13(1)		 17(1)	 13(1)		 ‐1(1)	 ‐2(1)		 0(1)	
C(6)	 20(1)		 22(1)	 18(1)		 1(1)	 3(1)		 ‐5(1)	
C(5)	 15(1)		 19(1)	 19(1)		 ‐2(1)	 2(1)		 1(1)	
C(18)	 22(1)		 17(1)	 21(1)		 ‐2(1)	 5(1)		 ‐1(1)	
C(15)	 17(1)		 27(1)	 19(1)		 ‐6(1)	 1(1)		 3(1)	
C(16)	 16(1)		 26(1)	 28(1)		 ‐12(1)	 4(1)		 ‐4(1)	
C(4)	 14(1)		 13(1)	 14(1)		 ‐1(1)	 ‐2(1)		 0(1)	
C(14)	 17(1)		 17(1)	 20(1)		 ‐1(1)	 2(1)		 0(1)	
C(7)	 23(1)		 15(1)	 18(1)		 1(1)	 ‐2(1)		 ‐3(1)	
C(13)	 14(1)		 16(1)	 19(1)		 ‐3(1)	 4(1)		 0(1)	
C(2)	 16(1)		 15(1)	 16(1)		 0(1)	 2(1)		 0(1)	
C(1)	 17(1)		 22(1)	 30(1)		 ‐4(1)	 7(1)		 0(1)	
C(3)	 15(1)		 14(1)	 17(1)		 0(1)	 2(1)		 1(1)	
C(17)	 24(1)		 21(1)	 30(1)		 ‐7(1)	 9(1)		 ‐7(1)	
C(8)	 17(1)		 15(1)	 18(1)		 ‐2(1)	 ‐2(1)		 2(1)	
C(11)	 24(1)		 26(1)	 18(1)		 5(1)	 ‐4(1)		 ‐3(1)	
C(12)	 19(1)		 21(1)	 24(1)		 7(1)	 ‐3(1)		 3(1)	
C(10)	 31(1)		 34(1)	 18(1)		 ‐1(1)	 7(1)		 ‐8(1)	
______________________________________________________________________________		
Table	S5.		Hydrogen	coordinates	(	x	104)	and	isotropic	displacement	parameters	(Å2x	10	3)	
for	v18441_a.	
________________________________________________________________________________		
	 x		 y		 z		 U(eq)	
________________________________________________________________________________		
		
 
 S41 
H(6)	 7403	 8221	 817	 24	
H(5)	 7263	 5491	 1303	 21	
H(18)	 1334	 1435	 3528	 24	
H(15)	 ‐1045	 3616	 ‐95	 25	
H(16)	 ‐2217	 1277	 610	 28	
H(14)	 1209	 4928	 1053	 22	
H(7)	 5271	 9976	 1312	 23	
H(1A)	 1208	 7577	 3790	 34	
H(1B)	 259	 5903	 3494	 34	
H(1C)	 521	 7125	 2448	 34	
H(17)	 ‐997	 178	 2414	 29	
H(8)	 3000	 9062	 2319	 20	
H(11A)	 5709	 3289	 5368	 28	
H(11B)	 5410	 5074	 4844	 28	
H(12A)	 6224	 2271	 3548	 26	
H(12B)	 7194	 3973	 3565	 26	
H(10A)	 2417	 5151	 5351	 41	
H(10B)	 2628	 3401	 5918	 41	
H(10C)	 1093	 3763	 4884	 41	
H(1)	 4270(40)	 3250(40)	 970(30)	 41	
________________________________________________________________________________		
	
Table	S6.	Torsion	angles	[°]	for	v18441_a.	
________________________________________________________________		
O(1)‐C(3)‐C(12)‐C(11)	 ‐142.05(14)	
N(1)‐C(9)‐C(4)‐C(5)	 ‐177.39(14)	
N(1)‐C(9)‐C(4)‐C(3)	 1.81(18)	
N(1)‐C(9)‐C(8)‐C(7)	 176.94(15)	
N(1)‐C(2)‐C(3)‐O(1)	 ‐131.12(14)	
N(1)‐C(2)‐C(3)‐C(4)	 ‐7.13(15)	
N(1)‐C(2)‐C(3)‐C(12)	 112.10(14)	
N(2)‐C(2)‐C(3)‐O(1)	 109.98(15)	
N(2)‐C(2)‐C(3)‐C(4)	 ‐126.02(13)	
N(2)‐C(2)‐C(3)‐C(12)	 ‐6.79(16)	
N(2)‐C(11)‐C(12)‐C(3)	 39.90(17)	
C(9)‐N(1)‐C(2)‐N(2)	 119.65(14)	
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C(9)‐N(1)‐C(2)‐C(13)	 ‐112.21(15)	
C(9)‐N(1)‐C(2)‐C(3)	 8.77(16)	
C(9)‐C(4)‐C(3)‐O(1)	 128.51(14)	
C(9)‐C(4)‐C(3)‐C(2)	 3.60(16)	
C(9)‐C(4)‐C(3)‐C(12)	 ‐108.43(15)	
C(6)‐C(5)‐C(4)‐C(9)	 ‐0.3(2)	
C(6)‐C(5)‐C(4)‐C(3)	 ‐179.31(15)	
C(6)‐C(7)‐C(8)‐C(9)	 1.0(2)	
C(5)‐C(6)‐C(7)‐C(8)	 0.7(2)	
C(5)‐C(4)‐C(3)‐O(1)	 ‐52.4(2)	
C(5)‐C(4)‐C(3)‐C(2)	 ‐177.28(15)	
C(5)‐C(4)‐C(3)‐C(12)	 70.7(2)	
C(18)‐C(13)‐C(2)‐N(1)	 ‐140.28(15)	
C(18)‐C(13)‐C(2)‐N(2)	 ‐11.3(2)	
C(18)‐C(13)‐C(2)‐C(3)	 104.65(18)	
C(15)‐C(16)‐C(17)‐C(18)	 0.8(3)	
C(15)‐C(14)‐C(13)‐C(18)	 1.0(2)	
C(15)‐C(14)‐C(13)‐C(2)	 178.65(15)	
C(16)‐C(15)‐C(14)‐C(13)	 1.3(2)	
C(4)‐C(9)‐C(8)‐C(7)	 ‐2.4(2)	
C(4)‐C(3)‐C(12)‐C(11)	 91.52(16)	
C(14)‐C(15)‐C(16)‐C(17)	 ‐2.2(2)	
C(14)‐C(13)‐C(2)‐N(1)	 42.1(2)	
C(14)‐C(13)‐C(2)‐N(2)	 171.16(14)	
C(14)‐C(13)‐C(2)‐C(3)	 ‐72.94(19)	
C(7)‐C(6)‐C(5)‐C(4)	 ‐1.1(2)	
C(13)‐C(18)‐C(17)‐C(16)	 1.5(3)	
C(13)‐C(2)‐C(3)‐O(1)	 ‐11.44(19)	
C(13)‐C(2)‐C(3)‐C(4)	 112.56(14)	
C(13)‐C(2)‐C(3)‐C(12)	 ‐128.21(14)	
C(2)‐N(1)‐C(9)‐C(4)	 ‐7.06(18)	
C(2)‐N(1)‐C(9)‐C(8)	 173.58(15)	
C(2)‐N(2)‐C(11)‐C(12)	 ‐46.46(17)	
C(2)‐C(3)‐C(12)‐C(11)	 ‐20.02(16)	
C(1)‐N(1)‐C(9)‐C(4)	 ‐162.46(14)	
C(1)‐N(1)‐C(9)‐C(8)	 18.2(2)	
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C(1)‐N(1)‐C(2)‐N(2)	 ‐86.00(19)	
C(1)‐N(1)‐C(2)‐C(13)	 42.1(2)	
C(1)‐N(1)‐C(2)‐C(3)	 163.12(14)	
C(17)‐C(18)‐C(13)‐C(14)	 ‐2.3(2)	
C(17)‐C(18)‐C(13)‐C(2)	 ‐179.94(15)	
C(8)‐C(9)‐C(4)‐C(5)	 2.0(2)	
C(8)‐C(9)‐C(4)‐C(3)	 ‐178.77(13)	
C(11)‐N(2)‐C(2)‐N(1)	 ‐78.14(17)	
C(11)‐N(2)‐C(2)‐C(13)	 154.50(14)	
C(11)‐N(2)‐C(2)‐C(3)	 32.81(17)	
C(10)‐N(2)‐C(2)‐N(1)	 49.8(2)	
C(10)‐N(2)‐C(2)‐C(13)	 ‐77.58(18)	
C(10)‐N(2)‐C(2)‐C(3)	 160.74(14)	
C(10)‐N(2)‐C(11)‐C(12)	 ‐176.45(15)	
________________________________________________________________		
Symmetry	transformations	used	to	generate	equivalent	atoms:		
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Absolute	Stereochemical	Assignment	of	(+)‐6:	
	
	
A	1	dram	vial	was	charged	with	(+)‐6	(5	mg,	12	µmol)	and	PhMe	(250	µL).	Red‐Al	(60	wt%	
in	 PhMe,	 32	 µL,	 99	 µmol,	 8.0	 equiv)	 was	 added	 dropwise.	 After	 stirring	 at	 ambient	
temperature	for	5	min,	the	vial	was	flushed	with	argon	and	sealed	with	a	Teflon	cap.	The	
reaction	was	then	stirred	at	80	°C	for	2.5	h.	The	reaction	was	cooled	to	room	temperature	
and	 then	 quenched	 slowly	with	 1	M	 aqueous	 solution	 of	 Rochelle’s	 salt	 (0.5	mL).	 The	
resulting	mixture	was	 stirred	 for	 1	 h	 and	 then	 extracted	with	 Et2O	 (1	mL	 x	 4)	 and	 the	
combined	organic	extracts	were	dried	(MgSO4),	 filtered,	and	concentrated	under	reduced	
pressure.	 The	 crude	 residue	 was	 purified	 by	 silica	 gel	 chromatography	 (10–20%	
EtOAc/hexanes)	 to	 afford	 (+)‐2	 (3.5	 mg,	 quant	 yield)	 as	 a	 yellow	 solid.	 The	 1H	 NMR	
spectrum	and	chiral	SFC	trace	were	consistent	with	those	of	(+)‐2.	
	
Chiral	SFC	trace	for	product	of	Red‐Al	reduction	of	(+)‐6	(15%	i‐PrOH/CO2):	
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Chiral	SFC	trace	for	(+)‐2	(15%	i‐PrOH/CO2):	
	
	
	
	
	
Absolute	Stereochemical	Assignment	of	(+)‐SI‐3:	
	
	
A	25	mL	round‐bottom	flask	was	charged	with	(+)‐SI‐3	(50	mg,	104	µmol)	and	PhMe	(2.1	
mL).	Red‐Al	 (60	wt%	 in	PhMe,	270	µL,	834	µmol,	8.0	equiv)	was	added	dropwise.	After	
stirring	at	ambient	temperature	for	5	min,	the	vial	was	flushed	with	argon	and	sealed	with	
a	Teflon	cap.	The	reaction	was	then	stirred	at	80	°C	 for	2.5	h.	The	reaction	was	cooled	to	
room	temperature	and	then	quenched	slowly	with	1	M	aqueous	solution	of	Rochelle’s	salt	
(2.5	mL).	The	resulting	mixture	was	stirred	for	1	h	and	then	extracted	with	Et2O	(4	mL	x	4)	
and	 the	combined	organic	extracts	were	dried	 (MgSO4),	 filtered,	and	concentrated	under	
reduced	pressure.	The	crude	residue	was	purified	by	silica	gel	chromatography	(10–20%	
EtOAc/hexanes)	to	afford	(+)‐2	(28	mg,	96%	yield)	as	a	yellow	solid.	The	1H	NMR	spectrum	
and	chiral	SFC	trace	were	consistent	with	those	of	(+)‐2.	
	
	
(+)‐2 
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Chiral	SFC	trace	for	product	of	Red‐Al	reduction	of	(+)‐SI‐3	(15%	i‐PrOH/CO2):	
	
	
	
	
Chiral	SFC	trace	for	(+)‐2	(15%	i‐PrOH/CO2):	
	
	
	
	
	
	
	 	
(+)‐2 
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6.	Chiral	SFC	Traces	for	Compounds	7–15,	SI‐4,	16	
7	(30%	i‐PrOH/CO2)	
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8	(20%	i‐PrOH/CO2)	
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Title PROTON01
Origin Varian
Solvent cdcl3
Temperature 25.0
Pulse Sequence s2pul
Experiment 1D
Number of Scans 16
Receiver Gain 30
Relaxation Delay 1.0000
Pulse Width 5.8000
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Spectrometer Frequency 499.64
Spectral Width 8000.0
Nucleus 1H
Acquired Size 24000
Spectral Size 65536
(+)-10
S77
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
0.
98
3.
04
1.
01
1.
04
2.
91
2.
99
1.
00
0.
96
0.
97
0.
98
0.
99
3.
01
1.
81
2.
11
2.
42
2.
46
2.
54
2.
64
2.
82
3.
02
6.
43
6.
69
7.
11
7.
22
7.
34
7.
45
Parameter Value
Title PROTON01
Origin Varian
Solvent cdcl3
Temperature 25.0
Pulse Sequence s2pul
Experiment 1D
Number of Scans 16
Receiver Gain 30
Relaxation Delay 1.0000
Pulse Width 5.8000
Acquisition Time 3.0000
Spectrometer Frequency 499.64
Spectral Width 8000.0
Nucleus 1H
Acquired Size 24000
Spectral Size 65536
(–)-10
S78
-100102030405060708090100110120130140150160170180190200210
ppm
33
.7
6
36
.5
1
37
.6
3
51
.5
1
52
.4
1
96
.1
6
96
.2
6
10
4.
14
11
6.
38
12
4.
82
12
7.
54
12
7.
68
12
7.
89
12
9.
64
12
9.
94
13
7.
84
15
2.
90
Parameter Value
Title CARBON01
Origin Varian
Solvent cdcl3
Temperature 25.0
Pulse Sequence s2pul
Experiment 1D
Number of Scans 512
Receiver Gain 30
Relaxation Delay 1.0000
Pulse Width 4.6125
Acquisition Time 1.0420
Acquisition Date 2018-07-05T20:32:56
Spectrometer Frequency 125.65
Spectral Width 31446.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(+)-10
S79
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
0.
91
1.
99
3.
01
1.
02
3.
06
1.
00
1.
02
1.
25
1.
84
2.
11
1.
37
2.
23
2.
47
2.
57
2.
73
3.
04
6.
21
7.
32
7.
39
7.
46
Parameter Value
Title JYS-3-51-F1-C5-iodo-pyrroloindoline-dash.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 127.1
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(–)-11
S80
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
0.
95
2.
06
2.
98
1.
05
3.
03
1.
00
1.
03
1.
40
1.
95
2.
19
1.
36
2.
21
2.
47
2.
55
2.
73
3.
04
6.
21
7.
32
7.
39
7.
47
Parameter Value
Title JYS-3-50-F1-C5-iodo-pyrroloindoline-wedge.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.2
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 156.2
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(+)-11
S81
-100102030405060708090100110120130140150160170180190200210
ppm
34
.4
7
36
.6
6
40
.6
8
51
.5
1
90
.2
7
98
.7
4
10
6.
58
12
8.
43
12
9.
05
13
2.
73
13
3.
70
13
6.
80
13
8.
50
15
2.
18
Parameter Value
Title JYS-3-51-F1-C5-iodo-pyrroloindoline-dash.2.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.2
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 512
Receiver Gain 78.7
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(–)-11
S82
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
0.
82
2.
05
3.
02
1.
12
3.
09
1.
00
1.
00
3.
15
2.
18
1.
41
2.
27
2.
50
2.
56
2.
80
3.
06
6.
42
7.
36
7.
45
Parameter Value
Title JYS-3-59-F1-dash-C5-CF3.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.2
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 156.2
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(+)-12
S83
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
0.
92
2.
04
3.
05
1.
10
3.
11
1.
00
1.
01
3.
10
2.
26
1.
40
2.
27
2.
50
2.
56
2.
80
3.
06
6.
42
7.
36
7.
45
Parameter Value
Title JYS-3-58-F1-wedge-C5-CF3.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 156.2
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(–)-12
S84
-100102030405060708090100110120130140150160170180190200210
ppm
34
.3
8
36
.6
6
40
.7
1
51
.4
6
90
.1
5
99
.0
4
10
3.
51
12
1.
45
12
1.
49
12
1.
53
12
1.
56
12
3.
91
12
6.
59
12
7.
89
12
7.
92
12
7.
96
12
8.
00
12
8.
58
12
9.
14
13
1.
09
13
6.
58
15
4.
82
Parameter Value
Title JYS-3-58-F1-wedge-C5-CF3.2.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 512
Receiver Gain 55.5
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(–)-12
S85
-190-180-170-160-150-140-130-120-110-100-90-80-70-60-50-40-30-20-1001020
ppm
-6
0.
44
Parameter Value
Title FLUORINE01
Origin Varian
Solvent cdcl3
Temperature 25.0
Pulse Sequence s2pul
Experiment 1D
Number of Scans 16
Receiver Gain 30
Relaxation Delay 1.0000
Pulse Width 6.3333
Acquisition Time 0.9856
Acquisition Date 2019-03-05T12:16:02
Spectrometer Frequency 282.34
Spectral Width 64935.1
Nucleus 19F
Acquired Size 64000
Spectral Size 131072
(+)-12
S86
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.5
ppm
0.
85
1.
94
2.
91
1.
05
2.
95
1.
00
0.
96
3.
15
2.
15
1.
38
2.
23
2.
47
2.
56
2.
73
3.
04
6.
29
7.
30
7.
39
Parameter Value
Title JYS-2-282-F1-C5-Br-plus.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 87.8
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(+)-13
S87
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
0.
91
2.
03
2.
92
1.
07
2.
91
1.
00
0.
95
3.
10
2.
06
1.
37
2.
23
2.
47
2.
58
2.
73
3.
04
6.
29
7.
30
7.
39
Parameter Value
Title JYS-2-281-F1-C5-Br-minus.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 87.8
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(–)-13
S88
-100102030405060708090100110120130140150160170180190200210
ppm
34
.5
7
36
.6
5
40
.7
0
51
.5
0
90
.3
4
98
.8
7
10
5.
66
10
8.
24
12
7.
11
12
8.
42
12
9.
04
13
2.
57
13
3.
07
13
6.
83
15
1.
59
Parameter Value
Title JYS-2-282-F1-C5-Br-plus.2.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 384
Receiver Gain 55.5
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(+)-13
S89
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.5
ppm
0.
85
1.
93
2.
79
1.
01
2.
79
1.
00
2.
84
0.
91
0.
92
0.
92
1.
20
2.
06
1.
38
2.
23
2.
47
2.
58
2.
72
3.
03
3.
76
6.
33
6.
80
6.
89
7.
31
7.
38
Parameter Value
Title JYS-2-285-F1-second-C5-OMe-plus.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 112.8
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(+)-14
S90
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
0.
87
1.
83
2.
73
1.
03
2.
73
1.
00
2.
77
0.
87
0.
90
0.
91
1.
23
2.
07
1.
38
2.
25
2.
46
2.
58
2.
72
3.
03
3.
76
6.
33
6.
80
6.
89
7.
31
7.
38
Parameter Value
Title JYS-2-284-F1-second-C5-OMe-minus.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.2
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 127.1
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(–)-14
S91
0102030405060708090100110120130140150160170180190200210
ppm
35
.0
7
36
.7
1
40
.7
65
1.
66
56
.3
0
90
.8
8
98
.9
2
10
4.
45
11
0.
64
11
5.
48
12
8.
15
12
8.
93
13
1.
87
13
7.
45
14
7.
28
15
2.
34
Parameter Value
Title JYS-2-285-F1-second-C5-OMe-plus.2.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.2
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 128
Receiver Gain 50.3
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(+)-14
S92
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
1.
08
2.
08
3.
18
1.
16
3.
11
5.
16
4.
17
1.
00
1.
04
1.
14
4.
08
1.
37
2.
24
2.
46
2.
58
2.
72
3.
04
3.
85
6.
35
6.
84
6.
97
7.
26
7.
30
7.
38
Parameter Value
Title JYS-2-287-F1-C5-morpholino.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.2
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 142.8
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(–)-15
S93
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.5
ppm
1.
03
2.
00
3.
01
1.
12
2.
96
4.
96
4.
03
0.
96
1.
05
1.
15
4.
08
1.
38
2.
24
2.
47
2.
58
2.
72
3.
05
3.
85
6.
35
6.
84
6.
97
7.
36
Parameter Value
Title JYS-2-286-F1-C5-morpholino-minus.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 127.1
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(+)-15
S94
-100102030405060708090100110120130140150160170180190200210
ppm
34
.9
3
36
.7
2
40
.7
0
51
.6
5
51
.8
4
67
.3
3
90
.9
7
98
.8
5
10
4.
35
11
4.
48
11
8.
70
12
8.
16
12
8.
92
13
1.
92
13
7.
46
14
3.
69
14
7.
78
Parameter Value
Title JYS-2-287-F1-C5-morpholino.2.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 512
Receiver Gain 87.8
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(–)-15
S95
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
2.
62
2.
63
4.
01
0.
15
1.
00
2.
63
1.
40
2.
62
8.
78
3.
03
1.
10
2.
91
3.
41
3.
56
4.
50
4.
71
5.
04
7.
16
7.
22
7.
34
7.
57
7.
64
Parameter Value
Title JYS-3-40-F1-aryl-Br-indole.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 127.1
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
SI-2
S96
-100102030405060708090100110120130140150160170180190200210
ppm
25
.2
6
30
.9
7
41
.7
6
66
.6
2
10
9.
65
11
0.
16
11
9.
09
11
9.
82
12
2.
35
12
2.
78
12
7.
51
12
8.
18
12
8.
21
12
8.
65
13
0.
70
13
1.
93
13
2.
26
13
6.
77
13
7.
36
13
7.
65
15
6.
30
Parameter Value
Title JYS-3-40-F1-aryl-Br-indole.2.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 512
Receiver Gain 72.0
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
SI-2
S97
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
2.
32
2.
52
2.
51
2.
98
3.
59
1.
34
1.
49
2.
46
0.
98
3.
75
1.
00
1.
21
4.
29
5.
27
15
.6
0
5.
02
1.
51
2.
20
2.
43
2.
75
3.
00
3.
16
3.
26
3.
99
4.
80
5.
04
6.
50
6.
56
6.
79
7.
13
7.
27
7.
51
Parameter Value
Title JYS-3-44-F3-SFC-F1-dash-Cbz-C2arylBr.3.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 98.9
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(+)-SI-3
S98
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
2.
77
2.
49
2.
46
2.
94
3.
59
1.
35
1.
48
2.
41
1.
04
3.
76
1.
00
1.
18
0.
25
4.
01
5.
23
8.
56
6.
70
4.
96
1.
51
2.
20
2.
43
2.
75
3.
00
3.
16
3.
26
3.
99
4.
80
5.
07
6.
50
6.
56
6.
79
7.
13
7.
27
7.
34
7.
51
Parameter Value
Title JYS-3-44-F3-SFC-F1-dash-Cbz-C2arylBr.3.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 98.9
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(–)-SI-3
S99
-100102030405060708090100110120130140150160170180190200210
ppm
31
.3
2
31
.9
1
33
.8
4
34
.2
8
46
.2
5
46
.3
7
67
.0
1
67
.2
6
88
.9
1
90
.0
1
93
.2
2
93
.8
7
10
6.
78
10
6.
86
11
8.
24
11
8.
58
12
2.
43
12
2.
69
12
3.
78
12
7.
85
12
7.
97
12
8.
06
12
8.
11
12
8.
22
12
8.
42
12
8.
64
12
9.
26
13
1.
10
13
1.
78
13
1.
90
13
3.
44
13
5.
26
13
5.
52
13
6.
32
13
6.
70
15
0.
93
15
1.
11
15
4.
62
15
4.
91
Parameter Value
Title JYS-3-44-F3-SFC-F1-dash-Cbz-C2arylBr.4.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 512
Receiver Gain 78.7
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(+)-SI-3
S100
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
2.
14
3.
00
1.
29
1.
04
1.
00
0.
96
0.
97
1.
95
2.
07
1.
94
2.
15
2.
56
2.
65
2.
80
3.
12
6.
42
6.
63
7.
14
7.
33
7.
47
Parameter Value
Title JYS-3-57-F1-dash-NH-arylBr.1.fid
Origin Bruker BioSpin GmbH
Solvent CD3CN
Temperature 295.2
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 112.8
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(+)-SI-4
S101
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
1.
97
3.
06
1.
19
0.
99
1.
00
0.
98
0.
99
1.
96
2.
58
1.
96
2.
14
2.
56
2.
65
3.
10
6.
42
6.
63
7.
14
7.
33
7.
47
Parameter Value
Title JYS-3-56-F1-wedge-NH-arylBr.1.fid
Origin Bruker BioSpin GmbH
Solvent CD3CN
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 142.8
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(–)-SI-4
S102
-100102030405060708090100110120130140150160170180190200210
ppm
28
.5
6
42
.5
9
43
.7
9
90
.3
7
94
.5
5
10
5.
33
11
7.
60
12
1.
83
12
4.
71
13
0.
55
13
1.
31
13
1.
65
13
2.
09
14
0.
67
15
2.
53
Parameter Value
Title JYS-3-57-F1-dash-NH-arylBr.2.fid
Origin Bruker BioSpin GmbH
Solvent CD3CN
Temperature 295.1
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 1024
Receiver Gain 78.7
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(+)-SI-4
S103
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
0.
96
2.
23
3.
18
1.
24
3.
40
1.
00
1.
08
1.
06
2.
38
2.
27
1.
37
2.
24
2.
44
2.
54
2.
75
3.
01
6.
41
6.
71
7.
22
7.
49
Parameter Value
Title JYS-3-66-C2-arylBr-NMe-wedge-2.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 176.8
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(+)-16
S104
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
ppm
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Parameter Value
Title JYS-3-66-C2-arylBr-NMe-wedge-2.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 176.8
Relaxation Delay 1.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(–)-16
S105
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ppm
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Parameter Value
Title JYS-3-66-C2-arylBr-NMe-wedge-2.2.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 295.1
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 1024
Receiver Gain 87.8
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(+)-16
S106
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.5
ppm
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Parameter Value
Title JYS-3-99-F2-C2-aryl-OMe-rac.1.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 296.1
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 156.2
Relaxation Delay 1.0000
Pulse Width 12.5000
Acquisition Time 4.0894
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
(±)-SI-5
S107
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ppm
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Parameter Value
Title JYS-3-99-F2-C2-aryl-OMe-rac.2.fid
Origin Bruker BioSpin GmbH
Solvent CDCl3
Temperature 296.1
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 1024
Receiver Gain 72.0
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
(±)-SI-5
S108
